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Abstract
mTOR is a serine/threonine protein kinase that has been shown to be a key player in
the regulation of cell growth and proliferation. Furthermore, mTOR forms the
catalytic core of two known mTOR complexes, mTORC1 and mTORC2. These
complexes sense various intra and extracellular signals, and regulate cellular
processes that are critical for cell growth and proliferation. However, when
conventional mTOR signalling is deregulated, cellular homeostasis is disrupted,
resulting in a wide range of human diseases such as diabetes, neurodegeneration and
cancer. Due to its involvement in tumorigenesis, mTOR has attracted enormous
interest as a therapeutic target. Initially, the classical mTOR inhibitor rapamycin was
tested as a potential treatment. However, when the compound was assessed in clinical
trials, it proved to be of limited efficacy. This led to the design of novel types of
inhibitors, which are currently being evaluated. The results obtained with rapamycin
clearly indicated that our understanding of the mTOR signalling pathway is far from
complete.
In addition, mTOR is currently known to exist in two isoforms, which are
generated by alternative splicing of the transcript. These are known as mTORα and
mTORβ respectively. The mTORα protein was the first isoform discovered and is
2,549 residues long. mTORβ is approximately one third of the length at 706 amino
acids. Both proteins share identical C-terminal domains, but mTORβ lacks the N-
terminal HEAT and FAT repeats that mTORα possesses. Work done in our lab has
shown that mTORβ is capable of forming complexes with Raptor and Rictor, which
are the key components of mTORC1 and mTORC2. Furthermore, overexpression of
mTORβ transforms immortal cells and causes tumour formation in nude mice. It is
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thought that modulation of cell proliferation via the mTOR signalling pathway could
be achieved through mTORβ, which behaves as a protooncogene. Thus, mTORβ has
the potential to be used as a target for anti-cancer therapies.
The first chapter of my thesis consisted of comparative modelling of
mTORβ’s C-terminal region from the FRB domain to the kinase domain. The model
that was generated could then be used to give us insight into potential mechanisms for
the inhibition of mTOR by either rapamycin or ATP-competitive inhibitors.
The second chapter examined the effects of two different mutations in
mTOR’s kinase domain on its activity. A point mutation (S2215Y) and a deletion of
12 amino acids (12del) were introduced into the kinase domain of mTORβ. Mutant
proteins were expressed in HEK293 mammalian cells and the phosphorylation status
of various mTOR substrates was assessed under different experimental conditions.
The final chapter of my thesis described how a TAP-tag fusion protein was
created. This would have been used to search for novel mTORβ binding partners in
mammalian cells had I chosen to complete my PhD studies.
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Chapter 1: General Introduction
Overview of mTOR
Target of Rapamycin (TOR) first rose to prominence as the cellular target for the
macrocylic lactone, rapamycin in yeast cells. Further studies in higher eukaryotes
revealed that a similar protein existed in mammals, which was named the mammalian
target of rapamycin (mTOR). mTOR, also known as FRAP, RAFT1, SEPT and
RAPT1 (Harris & Lawrence, Jr. 2003b), is an evolutionarily conserved 289-kDa
serine/threonine kinase that belongs to the phosphatidylinositol kinase-related kinase
(PIKK) family (Laplante & Sabatini 2009). Other members of this family include
ATM, ATR, DNA-PK, SMG1 and TRRAP (Sengupta, Peterson, & Sabatini 2010);
(Hall 2008) Robitaille & Hall 2008). All the PIKK proteins possess a C-terminal
protein kinase domain that shares significant sequence similarity to the catalytic
domains of PI3Ks and PI4Ks (Wullschleger, Loewith, & Hall 2006). However, unlike
the PI3Ks and PI4Ks, mTOR does not display lipid kinase activity. Instead, mTOR is
capable of phosphorylating cellular proteins at two specific sites; a threonine or serine
residue followed by a proline (Thr/Ser-Pro), and a threonine or serine adjacent to a
large hydrophobic (Φ) amino acid (Φ-Ser/Thr-Φ) (Hall 2008). Besides its kinase
activity, mTOR has no other known enzymatic functions (Yip et al. 2010).
mTOR forms the catalytic core of two known, distinct signalling complexes;
mTORC1 and mTORC2. As the key components of the mTOR signalling pathway,
these complexes sense various intracellular and extracellular signals, and respond by
modulating the appropriate cellular processes to maintain cellular homeostasis. As
such, abundant experimental evidence suggests that deregulation of mTOR signalling
results in a host of human diseases ranging from diabetes to cancer and cardiac
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hypertrophy (Fig. 1.1). Due to its critical involvement in tumorigenesis, mTOR has
attracted enormous interest as a therapeutic target for the treatment of cancer.
It has also been shown that several isoforms of mTOR exist. mTORα was the
first mTOR isoform discovered, but a second isoform, denoted mTORβ has recently
been revealed (Panasyuk et al. 2009). The focus of my studies was to to elucidate the
mTORβ signalling pathway in both normal and cancerous cells.
Fig. 1.1, Diseases linked to dysregulated mTOR signalling and the corresponding
affected organs. (Dazert & Hall 2011)
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Subcellular localisation of mTOR and its importance in mTOR
signalling
Work conducted by several groups has led to the conclusion that mTOR is primarily
cytosolic. However, mTOR has also been found on the membranes of several
intracellular organelles such as the Golgi, endoplasmic reticulum and mitochondria
(Desai, Myers, & Schreiber 2002), (Drenan et al. 2004), (Liu & Zheng 2007),
(Sabatini et al. 1999), (Tirado et al. 2003), (Withers et al. 1997). These results are
consistent with the multitude of cellular activities that are regulated by the mTOR
complexes. Indeed, there is mounting evidence which suggests that mTOR signalling
could be regulated by membrane trafficking. For example, it appears that amino acids
are essential in the shuttling of mTORC1 to the lysosomal surface, where it is able to
respond to growth factors. The localisation of mTORC1 to the lysosome also implies
that it may play a direct role in the regulation of autophagy. This is possible because
autophagic membranes fuse with lysosomes, where their contents are then degraded.
The proximity of mTORC1 to the region of degradation places it in an ideal position
to phosphorylate and cause the inhibition of proteins that promote autophagy.
Unfortunately, the precise subcellular location(s) of mTORC2 is currently unknown.
Nevertheless, a recent study suggested that yeast TORC2 localises to specific, dot-like
domains on the plasma membrane (Berchtold & Walther 2009).
Also of interest is the existence of a Golgi/ER localisation sequence in
mTOR’s HEAT repeats. When GFP was fused to the HEAT repeats, it was later
detected at the Golgi/ER (Liu & Zheng 2007). Furthermore, Phosphatidic acid (PA) is
able to bind to mTOR’s FRB domain, which suggests that PA may mediate movement
of mTOR to cellular membranes. Finally, mTOR translocates between the cytoplasm
and the nucleus, but the mechanism for this process remains unknown.
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The structure of mTOR and the different mTOR isoforms
mTORα
In humans, the mTOR gene encodes a protein of 2,549 amino acids and is composed
of several conserved structural domains. At the extreme N-terminus of mTOR, there
are a series of 20 HEAT repeats (Andrade & Bork 1995). Each of the HEAT motifs is
~39 amino acids in length and possesses three highly conserved positions consisting
of the residues Proline, Aspartic acid and Arginine. Every HEAT repeat also contains
several conserved hydrophobic amino acids. It is thought that the structure of
mTOR’s HEAT repeats could resemble those of PP2A’s A subunit. In PP2A, each
individual HEAT repeat is formed from a pair of antiparallel α helices that stack
alongside other repeats to create an ordered array (Groves et al. 1999). The HEAT
region is postulated to mediate protein-protein interactions, due to the extensive
surface formed by its stacked helices. For example, the protein Gephyrin which is
required for the clustering of glycine receptors in neurons, interacts with one of
mTOR’s HEAT repeats. (Sabatini et al. 1999)
Adjacent to the HEAT motifs is the relatively large helical FAT (for FRAP,
ATM, TRAP) domain, which is common amongst the PIKKs. Overexpression of this
domain in yeast led to arrest of the G1 phase of the cell cycle (Alarcon et al. 1999). It
was thought that this could be due to the sequestration of requisite interacting proteins
away from TOR1. Downstream of the FAT domain is the FRB (for FKBP12-
rapamycin binding) domain. This portion of the mTOR protein is able to bind the
FKBP12-rapamycin complex, which inhibits mTOR kinase activity. A crystal
structure of the FRB domain bound to the FKBP12-rapamycin complex has been
elucidated (Choi et al. 1996). This model showed that there were numerous
interactions between rapamycin and FRB, but a smaller number of interactions
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between FKBP12 and FRB. These results suggest that FKBP12 presents rapamycin to
mTOR in a conformation that facilitates interaction with FRB. In addition to the FRB
domain, the C-terminal half of mTOR also contains the catalytic domain, followed by
a putative negative regulatory domain (RD) (Sekulic et al. 2000) and a FATC domain.
The potential negative regulatory domain is phosphorylated in response to growth
factors and insulin (Scott et al. 1998), (Nave et al. 1999), (Sekulic et al 2000). It has
been shown that the FATC domain is crucial for mTOR’s kinase activity. Deletion of
just one amino acid from this domain, or the addition of an epitope tag to the C-
terminus virtually abolishes the kinase activity of mTOR (Takahashi et al. 2000).
Furthermore, it is thought that FATC and FATN may interact and fold in a manner
that facilitates exposure of the catalytic domain. Moreover, a NMR study revealed
that the FATC domain forms a disulphide bridge between two conserved cysteine
residues (Dames et al. 2005). mTOR contains numerous phosphorylation sites:
Ser2448, Ser2481, Thr2446 and Ser1261. These are shown in Fig. 1.2.
Fig. 1.2, Schematic diagram of mTOR domains: The 2549-amino acid mTOR
protein is depicted above a scale indicating amino acid residue number. The different
mTOR domains are shown in grey and white. Other proteins that mTOR is known to
interact with or form complexes with have been shaded in various colours (Watanabe
et al. 2011) .
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mTORβ
mTORβ is 706 residues in length and is a splicing iso form of mTOR (see Fig. 1.3 for
a detailed schematic). The sole difference between the two isoforms is that mTORβ
lacks mTORα’s HEAT as well as the majority of its FATN domains. Furthermore,
mTORβ is a protein kinase that has the ability to stimulate cellular proliferation and to
control the cell cycle progression via the G1/S phase (Panasyuk et al 2009).
Downstream signalling is effected by mTORβ when it forms complexes with the
Rictor and Raptor proteins. In vitro, mTORβ has also been shown to phosphorylate
several mTORα substrates such as S6K1, PKB/AKT and 4EBP1 (Panasyuk et al
2009). Moreover, it has been demonstrated that overexpression of mTORβ transforms
immortal cells and causes tumour formation in nude mice (Panasyuk et al 2009).  It is
thought that modulation of cell proliferation via the mTOR signalling pathway could
be achieved through mTORβ, which behaves as a protooncogene. Thus, mTORβ has
the potential to be used as a target for anti-cancer therapies.
Fig. 1.3, Comparison of the mTORα and mTORβ proteins: The domains have
been colour coded in both proteins, so common domains share the same coloration.
mTOR
 HEAT        HEAT   FAT      FRB    KD
1
mTOR

2549a
a
1 706a
a
FIT FATC
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Comparative Modelling of mTOR
At present, no crystal structures exist for either the full-length mTOR protein or for its
kinase domain. In the interim, before the acquisition of crystallographic data, in silico
models may help us to develop more potent and effective mTOR inhibitors. In 2009,
Sturgill and Hall used homology modelling to produce a model of TOR’s catalytic
region from its FAT domain to near the end of the FATC domain (Sturgill & Hall
2009). In human TOR, this corresponded to amino acid residues 1906-2526. The
model was based on PI3KCγ’s crystal structure and is shown in Fig. 1.4. The creation
of this model allowed visualisation of the ATP-binding pocket, and use of molecular
docking software (MGL tools 1.6.0 with AutoGrid4 and AutoDock4 (Scripps))
revealed how ATP binds to mTOR. Furthermore, the model also showed that
activating mutations in TOR are located in the catalytic, helical and FIT domains.
Interestingly, oncogenic mutations in PI3KCα were also centred in the helical and
catalytic domains, as well as in helix kα11 of the C-terminus. Helix kα11 corresponds
to part of the FIT domain in TOR. The location of mutations in similar regions in the
two proteins provided further evidence that they also shared structural similarities.
Crucially, the model shed new light on potential mechanisms for the regulation of
TOR.
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Fig. 1.4, The model of TOR’s catalytic portion generated by using PI3KCγ as the
homologue. The different domains have been highlighted and clearly labelled.  The γ-
PO4 of ATP is visible in the ATP-binding pocket of TOR’s catalytic domain. (Sturgill
& Hall 2009)
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Overview of the mTOR Complexes
mTOR is known to nucleate at least two distinct protein complexes, which have been
denoted mTORC1 and mTORC2. Both mTORC1 and mTORC2 share common
subunits (mTOR, mLST8/GβL and deptor), but are differentiated by unique
components. Rapamycin in complex with the immunophilin FKBP12 is capable of
inhibiting mTORC1 by binding to the FRB domain of the mTOR subunit (Loewith et
al. 2002). In contrast to mTORC1, mTORC2 does not directly bind FKBP12-
rapamycin. The activity of the complex is unaffected by acute treatment with
rapamycin. Nevertheless, in approximately 20% of cancer cell lines, the assembly of
mTORC2 is disrupted by prolonged exposure to rapamycin. This has the consequence
of diminishing the cellular quantities of functional mTORC2. Why this phenomenon
is only observed in a subset of cancerous cell lines remains to be elucidated.
mTORC1 is sensitive to intracellular and extracellular signals such as the
cell’s energy status, growth factors and nutrients. When these are present in
abundance, mTORC1 stimulates anabolic and inhibits catabolic cellular processes.
However, when the cell is subjected to stress signals or starvation, mTORC1 activity
is curtailed. This ensures that biosynthetic rates in the cell are maintained at a level
that corresponds to a limited supply of raw materials for cell growth (Dunlop & Tee
2009), (Ma & Blenis 2009), (Reiling & Sabatini 2006). mTORC1 is known to play a
pivotal role in the regulation of protein synthesis via its downstream substrates 4E-
BP1 and S6K1. It has also been shown that mTORC1 stimulates the biogenesis of
ribosomes by augmenting the transcription of ribosomal RNAs and proteins. The
result is that the cell’s protein biosynthetic capacity is markedly increased (Inoki et al.
2005). Moreover, diminished mTORC1 signalling has the effect of promoting
macroautophagy. This is a process whereby certain intracellular components are
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degraded to yield amino acids and other biological materials for the continuation of
anabolic activities such as energy production and protein synthesis. In effect, it is a
mechanism that enables the cell to survive when faced with a dearth of nutrition. The
function of several transcription factors that are involved in mitochondrial metabolism
and lipid synthesis are also modulated by mTORC1.
The modulation of actin cytoskeleton organisation was the first cellular
function that was attributed to mTORC2. It has now come to light that mTORC2 is
also involved in the control of cell cycle progression and cell size (Rosner et al. 2009).
It is currently known that mTORC2 phosphorylates and activates three substrates;
protein kinase C (PKC), serum- and glucocorticoid-regulated kinase (SGK) and Akt.
These three proteins are all members of the AGC kinase family and regulate
anabolism, cell cycle progression and cell survival (Facchinetti et al. 2008), (Garcia-
Martinez & Alessi 2008), (Ikenoue et al. 2008), (Sarbassov et al. 2005). From a
therapeutic perspective, the study of Akt is particularly important due to its
involvement in cancer and diabetes. However, when compared with mTORC1, our
knowledge of mTORC2 signalling pales in comparison. This is largely due to the lack
of mTORC2 inhibitors, especially its indifference to the classical mTOR inhibitor
rapamycin. A diagram illustrating the different cellular functions that are regulated by
mTORC1 and mTORC2 is shown in Fig. 1.5.
Structural and Functional Analysis of mTORβ
28
Fig. 1.5, Cellular functions regulated by mTORC1 and mTORC2. The mTOR
kinase nucleates two distinct protein complexes termed mTORC1 and mTORC2.
mTORC1 responds to amino acids, stress, oxygen, energy and growth factors and is
acutely sensitive to rapamycin. It promotes cell growth by inducing and inhibiting
anabolic and catabolic processes, respectively, and also drives cell-cycle progression.
mTORC2 responds to growth factors and regulates cell survival and metabolism, as
well as the cytoskeleton. mTORC2 is insensitive to acute rapamycin treatment but
chronic exposure to the drug can disrupt its structure. (Laplante & Sabatini 2012)
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The Structure of mTORC1
mTORC1 is composed of at least 5 different protein subunits. These include mTOR,
which acts as the catalytic subunit of the complex; proline-rich AKT substrate 40kDa
(PRAS40); regulatory-associated protein of mTOR (Raptor); mammalian lethal with
Sec13 protein 8 (mLST8, aka GβL); and DEP-domain-containing mTOR-interacting
protein (Deptor) (Peterson et al. 2009). mTOR, Raptor and mLST8 are indispensable
for mTORC1 to mediate its cellular functions (Loewith et al. 2002), (Kim et al. 2002),
(Kim et al. 2003). Unfortunately, the precise function(s) of most of the component
proteins remains an unknown quantity. In 2007, the cryo-EM structure of yeast TOR
in complex with KOG1, which is the yeast counterpart of Raptor was elucidated. The
25Å structure showed that TOR’s N-terminal HEAT repeats form a curved tubular-
shaped domain that interacts with KOG1’s WD40 repeat domain in the C-terminus. In
addition, KOG1’s N-terminus is in the vicinity of TOR’s kinase domain. It is thought
that due to its propinquity to the catalytic region, KOG1’s functions could be to
recruit and present substrates to the kinase domain (Adami et al. 2007). A cryo-EM
structure for mTORC1 has also been obtained. This model showed that mTORC1
exists as an obligate dimer that has a rhomboid shape and an aperture in its centre
(Yip et al. 2010). See Figs 1.6 and 1.7.
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Fig. 1.6, Cryo-EM structure of mTORC1. The proposed locations of the N- and C-
termini of mTOR have been marked and the purple star is the expected location of the
kinase domain. The black lines I and II demarcate the two interaction faces formed by
each mTOR molecule with the two raptor subunits. Antibody labelling was used to
determine the positions of mLST8 and PRAS40 (green asterisk). (Yip et al. 2010)
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Fig. 1.7, Cryo-EM Reconstruction of mTORC1 filtered to 26Å, with the main
structural features denoted. The protein has been shown from different angles and
the locations of PRAS40, mLST8 and raptor have been marked. The scale bar
represents 5nm. (Yip et al. 2010)
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Raptor
Raptor behaves as an adaptor protein in mTORC1 by firstly binding and then
presenting substrates to mTOR (Hara et al. 2002), (Kim et al. 2002). It has a MW of
~150kDa and its structural composition consists of an N-terminal RNC (raptor N-
terminal conserved) domain adjacent to a set of three HEAT repeats and seven WD-
40 repeats in the protein’s C-terminus (Kim et al. 2002), (Kim et al. 2003).
mLST8
mLST8 has been shown to form an association with mTOR’s kinase domain and to
promote the kinase activity of mTOR (Kim et al. 2003). Nonetheless, it does not
appear to be essential for the association of Raptor with mTOR (Guertin et al. 2006).
The protein has a MW of 36-kDa and consists of seven WD40 repeats.
PRAS40 and Deptor
Both Deptor and PRAS40 have been defined as negative modulators of mTORC1
(Peterson et al. 2009), (Sancak et al. 2007), (Vander et al. 2007). Recruitment of
PRAS40 and Deptor to mTORC1 stimulates mTORC1’s inhibition. It is thought that
PRAS40 modulates mTORC1 kinase activity by directly preventing the binding of
substrates (Wang et al. 2007). Activation of mTORC1 results in it phosphorylating
PRAS40 and Deptor. The physical interaction between mTORC1, PRAS40 and
Deptor is then weakened, which serves to augment mTORC1 signalling to an even
higher degree (Peterson et al. 2009), (Wang et al. 2007).
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The Structure of mTORC2
In addition to mTOR, Deptor and mLST8 which are also possessed by mTORC1,
mTORC2 also contains rapamycin-insensitive companion of mTOR (Rictor); protein
observed with Rictor-1 (Protor-1) and mammalian stress-activated protein kinase
interacting protein (mSIN1). A body of results supports the hypothesis that Rictor and
mSIN1 exert a stabilising influence on one another, thereby creating the basis for
mTORC2’s structural foundation (Frias et al. 2006), (Jacinto et al. 2006). Protor-1 and
Rictor also interact, but the significance of this association in unclear (Thedieck et al.
2007),. Mirroring its role in mTORC1, Deptor also regulates mTORC2 by exerting an
inhibitory affect on its activity (Peterson et al. 2009). To date, Deptor is the only
endogenous mTORC2 inhibitor that is known to exist. mLST8 is critical for the
viability of mTORC2, since knockout of the protein gravely reduced the activity and
stability of the complex (Guertin et al. 2006). A diagram showing the various proteins
contained in mTORC1 and mTORC2 is shown in Fig. 1.8. A schematic showing the
different mTOR complex components is displayed in Fig. 1.9.
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Deptor
Deptor
PRAS40
Protor1
Fig. 1.8, The core components of the mTOR Complexes: The two distinct mTOR
complexes are depicted. mTORC1 and mTORC2 both contain mTOR, Deptor and
mLST8. The other proteins are unique to one of the complexes. mTORC1 possesses
Raptor and PRAS40 exclusively, whereas Rictor, SIN1 and Protor1 are exclusive to
mTORC2. Deptor is an inhibitor for both of the complexes. mLST8 binds to the
kinase domain of both complexes, and appears to have an critical role in their
assembly. Raptor functions as a scaffolding protein that links mTOR’s kinase domain
to mTORC1 substrates, which stimulates mTORC1 signalling. PRAS40 has been
characterised as both a competitive mTORC1 substrate and a mTORC1 inhibitor. The
function of Protor1 remains uncertain, but it has been shown that Rictor and mSIN1
promote the assembly and signalling of mTORC2. Rapamycin binds to its
intracellular receptor FKBP12 and the complex formed interacts with the FRB
domain in mTOR. The activity of mTORC1 is inhibited by rapamycin, whereas
mTORC2 is only inhibited by prolonged treatment with high concentrations of
rapamycin. (Modified from Bhaskar & Hay 2007)
Amino
Terminal
Carboxy
Terminal
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Fig. 1.9, Schematic of mTOR complex components. HEAT: a protein-protein
interaction structure of two tandem anti-parallel α-helices found in huntingtin,
elongation factor 3, PR65/A and TOR;; FAT: a domain structure shared by FRAP,
ATM, and TRRAP, all of which are PIKK family members; FRB:
FKBP12/rapamycin binding domain; FATC: FAT C-terminus; RNC: Raptor N-
terminal conserved domain; WD40: about 40 amino acids with conserved W and D
forming four anti-parallel beta strands; CRIM: conserved region in the middle; RBD:
Ras binding domain. (Yang & Guan 2007)
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mTORC1 Signalling
Role in protein synthesis
Prior to division, a cell must double in size and mass. This process necessitates an
augmentation in protein synthesis, which is dependent on a sufficient supply of
nutrients and the presence of growth factors. G protein-coupled receptors and receptor
Tyrosine kinases are activated by these extracellular signals. These in turn actuate key
signal transduction pathways such as the Ras-ERK (extracellular signal-regulated
kinase) pathway and the phosphoinositide 3-kinase (PI3K)-AKT pathway. mTORC1
signalling is then promoted by these upstream signal transduction networks. The
contribution that mTORC1 makes to the increase in protein synthesis is two-fold. In
the short-term (minutes) it activates translation, and on a longer time scale (hours) it
augments the cell’s overall translational capacity by augmenting the levels of certain
translational components and ribosomes.
mRNA translation is traditionally divided into the three stages of initiation,
elongation and termination. mTORC1 is currently known to regulate the initiation and
elongation phases of protein synthesis. Of critical importance is the control of
initiation since it is the rate-limiting step in the creation of new proteins. Initiation is
modulated by mTORC1 via its two downstream substrates 4E-BP1 and S6K1 (Hay &
Sonenberg 2004a), (Tee & Blenis 2005). Both S6K1 and 4E-BP1 contain TOS (TOR-
signalling) motifs which bind to raptor, resulting in their recruitment to mTORC1
(Nojima et al. 2003;Schalm et al. 2003). In 4E-BP1 the TOS motif is located in the
extreme C-terminus and consists of the sequence FEMDI (Phe-Glu-Met-Asp-Ile). The
TOS sequence in S6K1 is situated in its N-terminus and is composed of the residues
FDIDL (Phe-Asp-Ile-Asp-Leu) (Schalm et al. 2002). In vivo, this motif has been
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shown to be required for the phosphorylation of these proteins by mTORC1 (Schalm
& Blenis 2002).
When the cell is in a quiescent state, 4E-BP1 competes with the translation
initiation factor eIF4G for an overlapping binding site on eIF4E. The association of
4E-BP1 with eIF4E prevents it from interacting with eIF4G and forming the eIF4F
initiation complex. Contained within the initiation complex are eIF4E, eIF4G and
crucially, the RNA helicase eIF4A. It is thought that eIF4A unravels secondary
structure in 5’-UTRs (5’-untranslated regions) of mRNAs in order to permit the
ribosome’s 40S subunit and other accessory proteins to scan the mRNA and to find
the start codon. This unravelling action is critically important for the translation of
mRNAs that possess considerable secondary structure in their 5’-UTR regions. In
essence, hypophosphorylated 4EBP-1 binds to eIF4E preventing it from forming the
initiation complex, which inhibits translation. However, activated mTORC1
phosphorylates 4E-BP1 in a hierarchical manner on at least four of its numerous
phosphorylation sites. In human 4E-BP1, the residues of interest are Thr37, Thr46,
Thr70 and Ser65. Thr37 and Thr46 must be phosphorylated prior to the
phosphorylation of Thr70 and Ser65 (Proud 2006a). Please see Fig. 1.10 below for an
illustration. The addition of phosphate groups to Thr37/Thr46 is totally independent
of the TOS motif, but requires the 4E-BP1’s N-terminal RAIP motif (Arg-Ala-Ile-Pro)
(Wang et al. 2005), (Tee and Proud 2002). Phosphorylation of Thr70 and Ser65 leads
to the dissociation of 4E-BP1 from eIF4E. This results in the binding of eIF4G to
eIF4E and the creation of functional initiation complexes, thereby priming translation
(Fig. 1.11).
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Fig. 1.10, Hierarchical phosphorylation of 4E-BP1 by mTORC1 results in release
from eIF4E. Phosphorylation at four sites on 4E-BP1 occurs sequentially. mTORC1
directly phosphorylates the ‘priming’ sites Thr 37 and Thr 46, and then
phosphorylates THr70 and Ser65. (Hay & Sonenberg 2004b)
Fig. 1.11, Regulation of cap-dependent translation initiation by mTORC1 via 4E-
BP. Hypophosphorylated 4E-binding proteins bind tightly to eIF4E, preventing it
from interacting with eIF4G and thus inhibiting translation. When nutrients are
abundant, mTORC1 phosphorylates 4E-BPs in a hierarchical manner, releasing the
4E-BP from eIF4E. This results in the recruitment of eIF4G to the 5’ cap and allows
translation initiation to proceed. (Ma & Blenis 2009)
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S6K1 is a member of the AGC family of protein kinases and must be phoshporylated
at two sites in order to be fully activated. These include Thr229 in the kinase
domain’s activation loop and Thr389 in the C-terminal’s hydrophobic motif.
mTORC1 firstly phosphorylates S6K1 on Thr389, which produces a docking site for
phosphoinositide-dependent kinase 1 (PDK1). PDK1 then phosphorylates Thr229
which activates S6K1. This allows S6K1 to phosphorylate eIF4B on Ser422, resulting
in its recruitment to the translation pre-initiation complex (Holz et al. 2005). eIF4B is
a cofactor that significantly enhances the helicase activity of eIF4A when
phosphorylated on its Ser422 residue (Hershey 1991). This has the consequence of
greatly improving the efficiency and rapidity of translation initiation (Fig. 1.12).
Furthermore, the protein Programmed cell death 4 (PDCD4) binds to eIF4A and is
postulated to suppress eIF4A’s helicase action (Yang et al. 2003). Upon stimulation
with growth factors, S6K1 is able to phosphorylate PDCD4 on Ser67, resulting in its
degradation through the ubiquitin ligase β-TrCP (Dorrello et al. 2006). As such, the
phosphorylation of PDCD4 by S6K1 prevents PDCD4 from inhibiting eIF4A’s
helicase function. Moreover, the scaffold protein SKAR has been shown to associate
with the activated form of S6K1, and recruits active S6K1 to newly formed mRNAs,
where it augments the translational yield (Ma et al. 2008). In addition, Ribosomal
protein S6 (rpS6 or just S6) is a component of the small (40S) ribosomal subunit and
is phosphorylated by S6K1 when the environmental conditions favour cell growth and
proliferation. Nevertheless, the phosphorylation of S6 is markedly disrupted by
rapamycin, which insinuates that this could involve mTOR.
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Fig. 1.12, Phosphorylation of S6K1 by mTORC1 augments the efficiency and
rapidity of translation initiation. Growth factors and nutrients activate mTORC1
which then phosphorylates S6K1 on Thr389. This allows PDK1 to phosphorylate
S6K1 on Thr229, which fully activates the protein. S6K1 then phosphorylates eIF4B
on Ser422. eIF4B then associates with the eIF3 complex to facilitate cap-dependent
translation initiation. (Peterson & Sabatini 2005)
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Translation elongation is also regulated by mTORC1 via modulation of the
phosphorylation status of eEF2 (eukaryotic elongation factor 2). The customary
function of eEF2 is to assist in the translocation stage of elongation when it is
dephosphorylated and active. However, eEF2 is inactivated by the addition of a
phosphate group at its Thr56 residue by eEF2 kinase. eEF2 kinase is itself subject to
regulation by phoshporylation on at least three in inhibitory sites (Ser76, Ser359 and
Ser366 in human eEF2 kinase) by mTORC1 (Proud 2006b). Ser366 is phosphorylated
by S6K but the precise mechanism whereby mTORC1 mediates phosphorylation of
the other two residues is currently unknown. Consequently, mTORC1 signalling
dephosphorylates and activates eEF2 in part by inhibiting eEF2 kinase by
phosphorylation. Unphosphorylated and active eEF2 is then able to actuate the
elongation apparatus.
Ribosomes are composed of approximately 85-90 distinct proteins (r proteins)
and ribosomal RNAs (rRNAs). Translation of the r proteins is subject to regulation by
mTOR. Furthermore, rDNA transcription which takes places in the nucleolus, and is
primarily catalysed by RNA polymerase I (PolI), is also regulated by mTOR. It has
been shown that mTOR is requisite for rDNA transcription activation (Hannan et al.
2003). The phosphorylation and function of UBF (upstream binding factor), which is
an rDNA transcription factor is also positively modulated by mTOR. In the set of
experiments conducted by Hannan et al. it was observed that S6K1 plays a key role in
mediating the interaction between mTOR and its regulation of UBF an rDNA
transcription. PolI transcription is also controlled by mTOR via its modulation of TIF-
1A activity (Mayer et al. 2004). TIF-1A is a regulatory factor that is sensitive to the
availability of growth factors and nutrients. When rapamycin is administered to cells,
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TIF-1A is translocated into the cytoplasm, which has the consequence of inhibiting
the formation of the transcription initiation complex.
Control of Autophagy
When cells are subjected to environmental stressors such as starvation and hypoxia,
intracellular organelles are sequestered within autophagosomes and delivered to the
lysosome (vacuole) for degradation. The subsequent release of biological material in
the form of amino acids and other nutrients provides the raw material to sustain
anabolic cellular functions such as energy production and protein synthesis, which are
required for cell survival. It has been demonstrated that inhibition of mTORC1
augments autophagy, but activation of mTORC1 diminishes this process (Codogno &
Meijer 2005). The regulation of autophagy by mTORC1 has been shown to be
insensitive to treatment with rapamycin (Mayer, Zhao, Yuan, & Grummt
2004;Thoreen et al. 2009). Moreover, work conducted in the past couple of years by
three different groups has shown that mTORC1 modulates autophagy via control of a
protein complex comprising focal adhesion kinase family-interacting protein of
200kDa (FIP200), autophagy-related gene 13 (ATG13) and unc-51 like kinase 1
(ULK1) (Ganley et al. 2009;Hosokawa et al. 2009;Jung et al. 2009). These
experiments demonstrated that mTORC1 suppresses autophagy by the
phosphorylation and repression of ATG13 and ULK1. Furthermore, mTORC1 also
regulates the movement of nutrient transporters, which stimulates the uptake of
nutrients including amino acids, iron, lipoprotein and glucose (Edinger and Thompson
2002).
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Regulation of Lipid Synthesis
The biosynthesis of lipids is of paramount importance for the preservation of cellular
homeostasis. The lipids that cells produce (sphingolipids, glycerolipids, fatty acids,
phospholipids and cholesterol) are utilised for various purposes. These include acting
as an energy reserve and playing the role of signalling molecules. Additional
functions include serving as the building blocks for the biosynthesis of membranes
and providing the precursor molecules for the creation of numerous cellular products.
When errors occur in the processing or synthesis of lipids, several diseases can arise
such as type 2 diabetes and cancer.
Growth factors activate Rsk, Erk and Akt which leads to the phosphorylation
and inactivation of TSC1/2, the upstream negative regulator of mTORC1. The
subsequent activation of mTORC1, not only by the inhibition of TSC1/2, but also by
the phosphorylation of PRAS40 by Akt, leads to the cleavage of SREBP-1. SREPBP-
1 is a simple helix-loop-helix transcription factor that modulates lipid production by
regulating the expression of genes necessary for the generation of phosholipid, fatty
acid, triglyceride and cholesterol. mTORC1 mediated cleavage of SREBP-1 results in
the protein’s translocation from the ER where it is synthesised, to the nucleus where it
is able to act as a transcription factor. Once in the nucleus, SREBP-1 is able to induce
the expression of several genes that are required for lipogenesis. Fatty acid synthase
(FASN), glucokinase (GK) and acetyl-CoA carboxylase represent an eclectic
selection of these genes.
The biological process of adipogenesis consists of the creation of mature
adipocytes from adipose precursor cells. The adipogenic cascade involves
CCAAT/enhancer binding protein-β (C/EBP-β) and C/EBP-δ, which stimulate the
expression of C/EBP-α. C/EBP-α then engenders the expression of peroxisome
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proliferator-activated receptor-γ (PPAR-γ). PPAR-γ is a nuclear receptor. Stimulation
of PPAR-γ activity results in dramatic alterations in gene expression, which causes
the promotion of fatty acid uptake, production, esterification and deposition in the
newly formed adipocyte. There is a strong body of evidence suggesting that mTORC1
regulates adipogenesis by the activation of PPAR-γ. It is thought that mTORC1
mediates control of PPAR-γ via several mechanisms. When mTORC1 is active, it
triggers the phosphorylation of the 4E-BP proteins, which causes the release of eIF4E.
This results in the translation of C/EBP-α and –δ, which are key players in the
adipogenic signalling pathway. The expression of C/EBP-α and PPAR-γ is driven by
C/EBP-δ, which also initiates the activation of a feed-forward loop in which the
expression of the transcription factors PPAR-γ and C/EBP-α is induced in a reciprocal
fashion. When sufficient quantities of PPAR-γ have been produced, it will instigate
the expression of a plethora of lipogenic genes as aforementioned. Furthermore, the
cleaving of SREBP-1 by mTORC1 not only results in the synthesis of triglycerides,
but also promotes the generation of PPAR-γ’s endogenous ligands. This represents an
additional way by which mTORC1 may contribute to the stimulation of adipogenesis.
In addition, Lipin-1, which is a phosphatidic phosphatase, has been demonstrated to
possess an important function in adipogenesis. It serves as a coactivator for PPAR-γ
and promotes the production of triglycerides. Rapamycin diminishes the
phosphorylation of Lipin-1 (Huffman et al. 2002), but it is currently unknown whether
it is a substrate for mTORC1 or mTORC2. A diagram illustrating the regulation of
lipid synthesis by mTORC1 is shown in Fig. 1.13.
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Fig. 1.13, Regulation of lipid synthesis by mTORC1. The presence of growth
factors results in the inactivation of TSC1/2, and the activation of mTORC1.
mTORC1 then mediates the cleavage of the transcription factor SREPBP-1, resulting
in its translocation to the nucleus. Here, SREPBP-1 induces the expression of several
genes that are required by lipogenesis. mTORC1 activates PPARγ via several
mechanisms, which results in the expression of a plethora of lipogenic genes.
(Laplante & Sabatini 2012)
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Modulation of mitochondrial metabolism and biogenesis
mTORC1 regulates mitochondrial metabolism and biogenesis. When mTORC1 is
inhibited with rapamycin, the cellular ATP levels, oxygen consumption and
mitochondrial membrane potential are all diminished. Moreover, these changes
induce a profound alteration in the mitochondrial phosphoproteome (Schieke et al.
2006). Work conducted in the past few years has demonstrated that mitochondrial
DNA copy number and the expression of numerous genes that encode proteins
involved in oxidative metabolism are reduced by rapamycin. Nevertheless, they are
augmented by mutations that stimulate the mTORC1 pathway (Chen et al.
2008;Cunningham et al. 2007). Furthermore, when Raptor was conditionally deleted
in mouse skeletal muscle, it was observed that there was a reduction in the expression
of the genes that are involved in mitochondrial biogenesis (Bentzinger et al. 2008). It
has also been noted that mTORC1 regulates the PPARγ coactivator 1’s (PGC1-α)
transcriptional activity. PGC1-α is a nuclear cofactor that plays a critical role in
oxidative metabolism and mitochondrial metabolism by directly changing its physical
association with yin-yang 1 (YY1), which is another transcription factor
(Cunningham et al. 2007).
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Regulation of mTORC1
Overview
mTORC1 regulates numerous cellular processes that stimulate cell growth by
integrating four major signals. These are nutrients, energy status, growth factors and
stress. The appropriate downstream response is then initiated by mTORC1 to preserve
homeostasis within the cell. The tuberous sclerosis complex (TSC) is one of the
principal sensors involved in the modulation of mTORC1 activity. TSC is a
heterodimer that is composed of TSC1 (aka harmatin) and TSC2 (aka tuberin).
TSC1/2 acts as a GTPase-activating protein (GAP) for the small Ras-related GTPase
Rheb (Ras homologue enriched in brain). Rheb is activated by the addition of GTP,
and interacts directly with mTORC1, promoting its activity (Long et al. 2005),
(Sancak et al. 2007). TSC1/2’s GTPase activity is specific for Rheb, and it inhibits
mTORC1 signalling by converting Rheb into its inactive GDP-bound state (Inoki et al.
2003).
The effect of growth factors
Eukaryotes are reliant on long-range communication for the coordination of nutrient
distribution and the concomitant growth of cells. When the organism is well fed, the
concentrations of growth factors in the plasma will be sustained at a relatively high
level. This leads to the promotion of anabolic processes such as nutrient storage, lipid
biosynthesis and translation via stimulation of mTORC1 activity.
The quantities of growth factors circulating in the bloodstream are detected by
mTORC1 through its connection to the PI3K pathway and the TSC1/2 complex. The
binding of insulin or insulin-like growth factors to their cognate receptors results in
the recruitment and phosphorylation of insulin receptor substrate 1 (IRS1). PI3K is
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then recruited and binds to IRS1, where it converts phopsphatidylinositol-4,5-
phosphate (PIP2) in the cell membrane to phosphatidylinositol-3,4,5-phosphate (PIP3).
Akt and PDK1 are then both recruited to the membrane, where Akt is phosphorylated
and activated by PDK1. Akt in conjunction with other kinases such as p90 RSK1 and
MAPK that are downstream of growth factor signalling then phosphorylates TSC2
(Ballif et al. 2005), (Li et al. 2003), (Potter, Pedraza, & Xu 2002), (Roux et al. 2004),
(Roux et al. 2004;Tee et al. 2003). The consequence is the inactivation of the TSC1/2
complex and the activation of mTORC1. Furthermore, two other pathways are
currently known to regulate mTORC1 in response to growth factors. Extracellular
signal-regulated kinase (ERK), which is part of the (MEK)-ERK axis inhibits TSC2
by phosphorylation (Ma et al. 2005). The Wnt pathway, which regulates cell growth
and proliferation in adults, has also been shown to play a role in the modulation of
mTORC1 activity (Castilho et al. 2009;Inoki et al. 2006), (Inoki et al. 2006).
Glycogen synthase kinase 3β negatively regulates mTORC1 by phosphorylating
TSC2. By its inhibition of GSK3β, Wnt mediates the activation of mTORC1.
Mechanisms also exist whereby mTORC1 is regulated by growth factors
independently of TSC. For example, when Akt is activated by growth factors it
phosphorylates PRAS40 at Ser247 leading to its inactivation. This results in the
disruption of its inhibitory action on mTORC1 (Inoki et al. 2006;Oshiro et al. 2007),
(Sancak et al. 2007), (Thedieck et al. 2007), (Vander et al. 2007), (Wang et al. 2007),
(Wang et al. 2008).
Curiously enough, the activation of mTORC1 by growth factors also results in
the attenuation of growth factor signalling by means of the ‘negative feedback loop’.
Nevertheless, in stark contrast to conventional feedback loops where inhibition is only
initiated upon attainment of a certain threshold, mTORC1 appears to repress growth
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factor signalling pathways in an incremental and continuous manner. It is thought that
more than one mechanism is involved in the actuation of the feedback loop. When
S6K1 is active, it phosphorylates IRS1, which diminishes its expression and activity.
This impairs its binding to the insulin receptor, which leads to the promotion of
IRS1’s degradation and a decline in the quantities of its mRNA (Harrington et al.
2004), (Sancak et al. 2007), (Shah and Hunter 2006), (Tremblay et al. 2007).
Moreover, activated S6K1 is also capable of suppressing the function of other growth
factor receptors that are not dependent on IRS1. An example is platelet-derived
growth factor receptor (PDGFR), which demonstrates that IRS1 is not the sole target
in feedback inhibition (Zhang et al. 2003). It has also been shown that mTORC1 can
directly interact with IRS1 through Raptor. The result is the phosphorylation of IRS1
at residues that hinders its binding to PI3K (Tzatsos 2009).
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The role of amino acids
Amino acids stimulate mTORC1 activity. Furthermore, it has been shown that
arginine, and the branched chain amino acids leucine and isoleucine are particularly
important in the promotion of mTORC1 function (Hara et al. 1998). Studies that were
conducted more than ten years ago demonstrated that withdrawal of amino acids from
cultured cells resulted in the inhibition of mTORC1 activity. No other known
activating stimuli could force a resumption of mTORC1 signalling (Hara et al.
1998;Sancak et al. 2008;Wang et al. 1998). The level of amino acids can be detected
within the cell instead of at the plasma membrane in mammals (Christie et al. 2002).
As such, amino acid transporters, such as SLC7A5 have been shown to play an
important role in the mTORC1 pathway. SLC7A5, which is a bidirectional transporter,
imports Leucine into the cell via the concomitant efflux of glutamine (Nicklin et al.
2009).
However, the mechanisms by which amino acids activate mTORC1 signalling
once inside the cell are only beginning to be revealed. Nonetheless, it is known that
the stimulation of mTORC1 by amino acids is dependent on both Rag (Kim et al.
2008), (Sancak et al. 2008) and the Ras-like GTPase Rheb (Garami et al. 2003),
(Inoki et al. 2003a), which both directly bind to mTORC1. In addition, Rag brings
about the localisation of mTORC1 to the lysosomal membrane (Kim et al. 2008),
(Sancak et al. 2008). There are four Rag GTPases; RagA, RagB, RagC and RagD.
The heterodimeric Rag GTPase complex is formed by the binding of either RagA or
RagB to either RagC or RagD, and appears to be constitutively located on lysosomal
membranes. As individual components, the Rag GTPases are functionally redundant.
Furthermore, lysosomal membranes possess a multi-subunit complex that is
composed of p18, p14 and MP1, that is known as the Ragulator (Sancak et al. 2010).
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This complex plays the part of a scaffold protein for Rag. When cells are starved of
amino acids, RagC/D is bound to GTP, whereas RagA/B is bound to GDP.
Nonetheless, amino acid stimulation of the cells results in the switching of the bound
guanine nucleotides, via an unknown mechanism. RagA/B now binds GTP and
RagC/D binds GDP, resulting in the activation of Rag. Activated Rag then interacts
with Raptor and acts as a docking site for mTORC1 on the lysosome’s surface
(Sancak et al. 2008). Rheb-GTP, which exists in a lysosomal pool, then activates
mTORC1 through an unknown mechanism. Moreover, since Rheb is required for the
promotion of mTORC1 activity by all upstream inputs, it is speculated that the amino
acid dependent targeting of mTORC1 to lysosomal membranes is a prerequisite for
the stimulation of mTORC1 by all other signals (Sancak et al. 2008;Sancak et al.
2010). Other potential modulators of amino acid signalling to mTOR include the class
III PI3K mVps34 (Byfield et al. 2005;Nobukuni et al. 2005) and the Ste20-related
kinase MAP4K3 (Findlay et al. 2007). Unfortunately, the precise mechanisms by
which these proteins regulate mTORC1 remain to be elucidated.
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The importance of Energy Status
mTORC1 is sensitive to the energy level within the cell via AMP-activated protein
kinase (AMPK) (Hardie 2007). Energy deficiency, as signified by a high AMP/ATP
ratio activates AMPK, which then phosphorylates TSC2. This augments TSC2’s GAP
activity towards Rheb, which inhibits mTORC1 (Inoki, Zhu, & Guan 2003).
Furthermore, AMPK can diminish mTORC1 signalling when energy is insufficient by
directly phosphorylating Raptor (Gwinn et al. 2008). Furthermore, LKB1, which is a
tumour suppressor, has been shown to be an upstream kinase for AMPK. This implies
that LKB1 could form part of the TSC-mTORC1 signal transduction network.
Moreover, it was demonstrated that LKB1 mutant cells possessed vastly increased
mTORC1 signalling (Corradetti et al. 2004;Shaw et al. 2004).
The impact of stress and miscellaneous cellular signals
Hypoxia inhibits mTORC1 signalling via several mechanisms (Wouters &
Koritzinsky 2008). Oxygen deprivation results in a decline in the level of cellular
ATP by causing the inhibition of metabolic processes such as oxidative
phosphorylation. The subsequent elevation of the AMP:ATP ratio activates AMPK,
which dampens mTORC1 signalling through the promotion of TSC2 activation and
the phosphorylation of raptor (Arsham et al. 2003), (Liu et al. 2006). TSC1/2 can also
be activated by hypoxia via transcriptional regulation of the protein DNA damage
response 1 (REDD1) (Brugarolas et al. 2004), (Reiling & Hafen 2004). REDD1 is a
cytoplasmic protein that is 232 amino acids long. In addition it is thought to belong to
a signal transduction pathway that is parallel to PI3K and AMPK (Sofer et al. 2005).
Furthermore, it was observed that REDD1 inhibited mTORC1 signalling by liberating
TSC2 from its growth-factor induced binding to 14-3-3 proteins and stabilising the
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association of TSC1 and TSC2 (DeYoung et al. 2008), (Vega-Rubin-de-Celis et al.
2010). A variety of other cellular stressors such as cigarette smoke, oxidising agents
and DNA damage also induce REDD1 (Ellisen et al. 2002; Wang et al. 2003;Yoshida
et al. 2010). Moreover, signalling in the mTORC1 pathway is diminished during
hypoxia by another two proteins; BCL2/adenovirus E1B 19 kDa protein-interacting
protein 3 (BNIP3) and promyelocytic leukemia (PML) tumour suppressor. These
proteins mediate mTORC1 inhibition by preventing mTORC1 from interacting with
Rheb (Bernardi et al. 2006;Ellisen et al. 2002;Li et al. 2007).
When a cell’s DNA is damaged, one of two paths can be taken. If the DNA
damage is reversible, then cellular repair processes will be initiated. However, if the
situation is irrevocable, then apoptosis will be activated (Ciccia & Elledge 2010).
Furthermore, there is increasing realisation of the role that mTORC1 inhibition plays
in DNA repair (Ellisen et al. 2002;Ghosh et al. 2006). The tumour suppressor protein
p53 is a keystone in the regulation of DNA damage responses (Riley et al. 2008);
(Vousden & Ryan 2009). When p53 is activated by DNA damage, it negatively
modulates mTORC1 signalling by augmenting the transcription of TSC2, phosphatase
and tensin homologue deleted on chromosome 10 (PTEN) and REDD1, which have
all been implicated in the inhibition of mTORC1 activity (Ellisen et al. 2002; Feng et
al. 2005; Stambolic et al. 2001). In addition, p53 also augments the expression of the
genes for Sestrin1 and Sestrin2. These proteins are able to suppress mTORC1 through
AMPK-dependent modulation of TSC1/2 (Budanov & Karin 2008); Feng et al. 2005).
There is also limited evidence which insinuates that p53 induces a rapid decline in the
initiation of translation, in part by controlling the phosphorylation of 4E-BP1 and S6K
(Horton et al. 2002). Taken together, these findings suggest that p53 activation due to
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genotoxic stress suppresses mTORC1 function in a multi-faceted manner (Ellisen, et
al. 2002; Feng et al. 2005; Stambolic et al. 2001).
IκB kinase β (IKKβ) is one of the foremost activators of the proinflammatory
NF-κB signal transduction network. When stimulated by inflammatory cytokines such
as TNFα, IKKβ phosphorylates TSC1 causing its destabilisation (Lee et al. 2007).
This results in mTORC1 activation. The link between inflammation and the
promotion of mTORC1 function is speculated to be significant in insulin resistance
(Lee et al. 2008) and tumour angiogenesis (Lee et al. 2007).
Finally, numerous labs have demonstrated that overexpression of PA-
producing enzymes (i.e. PLD1 and PLD2), or exogenous PA markedly amplifies
mTORC1 signalling (Foster 2007). It is thought that PA achieves this by either
stabilising mTORC1 complexes, or by facilitating their assembly (Toschi et al. 2009).
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mTORC2 Signalling-Overview
When compared with mTORC1, very little is known about the regulation and
functions of mTORC2. This is largely due to the present lack of mTORC2 inhibitors.
Nevertheless, it has been shown that mTORC2 plays a pivotal role in several cellular
processes such as cell survival, metabolism, proliferation and the organisation of the
cytoskeleton.
mTORC2’s involvement in cell survival, metabolism and proliferation
Activation of AKT is of crucial importance in the positive modulation of cellular
survival, metabolism and proliferation via the phosphorylation of numerous effector
proteins (Manning & Cantley 2007). AKT is fully activated when it is phosphorylated
at two sites, namely Ser308 by the action of phosphoinositide-dependent kinase 1
(PDK1), and Ser473 by mTORC2 (Sarbassov et al. 2005). When mTORC2 is
depleted, AKT is inhibited. This leads to a diminution in the phosphorylation of
forkhead box protein O1 (FoxO1) and FoxO3a, which are both transcription factors
that regulate the expression of genes concerned with metabolism, stress resistance,
cell-cycle arrest and apoptosis (Calnan & Brunet 2008). Diminished phosphorylation
of these proteins inactivates them. Work done in the past few years has also shown
that serum- and glucocorticoid-induced protein kinase 1 (SGK1) is modulated by
mTORC2 (Garcia-Martinez & Alessi 2008). Unlike AKT, which still functions at a
minimal level when mTORC2 is deactivated, the activity of SGK1 is completely
abolished. Moreover, AKT and SGK1 phosphorylate FoxO1 and FoxO3a on common
residues. Therefore, it is plausible that the absence of SGK1 activity in cells that lack
mTORC2 leads to the inhibition of FoxO1 and FoxO3a phosphorylation.
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Control of Cytoskeletal Organisation
Recent work has shown that mTORC2 regulates the organisation of the actin
cytoskeleton by various means. These include enhancing the phosphorylation of
protein kinase Cα (PKCα) as well as phosphorylating paxillin and relocating it to
focal adhesions. The addition of GTP to RhoA and Rac1 has also shown to  be
important in the control of the actin cytoskeleton by mTORC2 (Jacinto et al. 2004),
(Sarbassov et al. 2004), but the precise mechanisms by which mTORC2 controls these
processes is still unknown.
Signalling upstream of mTORC2
Unfortunately, the upstream molecular events that lead to the activation of mTORC2
are not fully defined. However, upon growth factor stimulation, mTORC2 kinase
activity is elevated, and it phosphorylates AKT in its C-terminal hydrophobic motif at
residue Ser473 (Guertin & Sabatini 2007). In addition, in vitro tests have
demonstrated that in order for AKT to be fully activated, it must be phosphorylated at
both Ser473 and at Thr308. However, the phosphorylation of the Thr308 residue by
PDK1 is not dependent on Ser473 phosphorylation (Biondi et al. 2001), (Collins et al.
2003). In addition, the mTORC2 component mSIN1 possesses a pleckstrin homology
domain at its C-terminus. As such, it is speculated that mSIN1 may mediate the
shuttling of mTORC2 to the membrane. Here, it would be able to interact with AKT
via its PH domain and phosphorylate it at Ser473 (Schroder et al. 2007). In Fig. 1.14,
a diagram showing a simplified version of the mTOR signalling network has been
provided.
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Figure 1.14: The mTOR signaling network. This is a simplified representation of
the mTOR signalling pathway that demonstrates how the mTORC1 and mTORC2
complexes regulate growth and metabolism in the cell. Amino acids (purple)
positively modulate the rapamycin-sensitive mTORC1 through the Rag GTPases.
Growth factors (green) regulate mTORC1 activity in a positive manner via the Akt-
PI3K pathway. Growth factors also stimulate mTORC2 function via an unknown
pathway that involves the TSC complex. Low energy status (yellow) inhibits
mTORC1 through AMPK. The mTORC substrates have been coloured grey. (Polak &
Hall 2009)
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mTOR as a Therapeutic Target
Due to the key role mTOR plays in the regulation of cellular growth and proliferation,
mTOR is under intense investigation as a therapeutic target primarily for cancer. The
earliest clinical trials involved the use of the classical mTOR inhibitor rapamycin.
However, the results were disappointing because rapamycin proved to be of limited
efficacy in the treatment of certain types of cancer. Research has shown that some of
the key problems stem from its inability to directly inhibit mTORC2, the inhibition of
the negative feedback loop upon mTORC1 inactivation and its poor solubility in
water (Napoli & Taylor 2001). In order to remedy the problem of insolubility,
rapalogues such as Temsirolimus and Everolimus were developed. Despite their
modifications, these drugs are still capable of mimicking the inhibitory action of the
FKBP12-rapamycin complex on mTOR. Their potency is currently being assessed in
ongoing clinical tests.
The indifference that mTORC2 displayed towards rapamycin treatment also
spurred the development of ATP-competitive inhibitors. These target mTOR’s
catalytic site and inhibit all mTORC1 and mTORC2 functions. Examples include
Torin (Thoreen et al. 2009), P30 (Feldman et al. 2009), WAY-600 (Yu et al. 2009)and
Ku-0063794 (Garcia-Martinez et al. 2009). The effect of inhibiting all mTOR
functions on cell viability requires further investigation.
Attempts have been made to circumvent the issue of feedback inhibition by
using dual PI3K-mTOR inhibitor strategies. So far inhibitors such as NVP-BEZ235
have been proven to possess superior anti-proliferative abilities when compared with
rapalogues such as Everolimus in 21 different cancer cell lines (Serra et al. 2008).
However, although inhibition of both mTOR and PI3K proved to be an effective
treatment in tumours that displayed hyperactive PI3K signalling (Brachmann et al.
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2009), it was ineffective when faced with hyperactivation of K-Ras. It appears that in
the case of Ras-driven tumorigenesis, the simultaneous inhibition of mTOR, PI3K and
Ras’s downstream mediators is necessary (Engelman et al. 2008), (Ihle et al.
2009;Torbett et al. 2008). However, the potential toxicity of this approach has not yet
been critically evaluated (Adami et al. 2007).
Mutations in mTOR
In 2010, Sato et al mined the COSMIC library (Catalogue of Somatic Mutations in
Cancer) provided by the Sanger Institute. This database contains a huge quantity of
information pertaining to somatic mutations in human cancers. The results of the
search showed that 10 mutations in the mTOR gene have currently been identified
from 750 cancer samples. Two of these mutations were silent mutations that did not
alter the amino acid sequence. Another generated a stop codon that resulted in the
production of a truncated mTOR protein that lacked a kinase domain. The mutation
M135T was identified twice. The 6 different mutations that resulted in a change in
amino acid are shown in Fig. 1.15. Of particular interest were the mutations that were
located in the kinase domain or its vicinity. These were S2215Y, P2476L and R2505P
respectively.
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Fig 1.15, The locations of the 6 mutations identified in mTOR. Each of these 6
mutations results in a change in amino acid. The tissue type in which each of the
mutations was found has also been indicated. (Sato et al. 2010)
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Aims of this Study
Several years ago, an isoform of mTOR was discovered in the Gout lab, which was
called mTORβ. The initial set of experiments performed revealed some key findings;
the protein was able to form the mTORC1 and mTORC2 complexes and was a proto-
oncogene. However, in order to further our understanding of the function and
regulation of this novel protein, it was decided to gain insight into its structure.
Therefore, the first part of my PhD studies involved comparative modelling of
mTORβ’s kinase domain. The effect of mutations on the kinase activity of mTORβ
towards several mTOR substrates was then assessed in mammalian cells. Finally, a
mTOR/TAP-tag fusion protein was generated. Had time permitted, this would have
been used to search for novel mTORβ binding partners.
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Chapter 2
Materials and Methods
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Chapter 2: Materials and Methods
2.1) Materials
2.1.1 Common Chemicals and Reagents
All the general purpose chemicals were acquired from Sigma-Aldrich, Thermo Fisher
Scientific UK limited, BDH Biosciences unless otherwise specified. General cell
culture reagents were purchased from PAA Laboratories GmbH. Pre-stained protein
molecular weight markers, restriction enzymes and DNA markers were obtained from
Fermentas.
2.1.2 Antibodies
Horseradish peroxidase-linked (HRP) secondary antibodies (anti-rabbit and anti-
mouse) were purchased from Promega. Antibodies against actin, myc and EE were
generated in the lab by former students for other purposes. Anti-Akt (#9272), anti
Phospho-Akt (#4051), anti 4E-BP1 (#9452) and anti Phospho-4E-BP1 (#2855) were
obtained from Cell Signalling. Anti-S6K1 (ab32359) and anti-S6K1 (phosphpoT389)
(ab2571) were acquired from Abcam. Anti-Phospho-mTOR (Ser2448) (09-213) and
anti-mTOR (07-231) antibodies were obtained from Millipore.
2.1.3 Mammalian cells
HEK293 cells were obtained from the American Type Culture Collection (ATCC).
2.1.4 Plasmids and Primers
The pCeMM-NTAP(GS) plasmid was obtained courtesy of Dr Tilmann Burckstummer
from the Research Centre for Molecular Medicine of the Austrian Academy of Sciences. All
other plasmids were obtained from Invitrogen. Primers were ordered from MWG Operon.
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2.2 Experimental Methods
2.2.1 Nucleic Acid Manipulation
2.2.1.1 Digestion of DNA with specific restriction enzymes
All restriction endonucleases were acquired from Fermentas and digests were carried
out in the manufacturer’s recommended digestion buffer. 5 units of restriction enzyme
were used to digest 1μg of DNA in a total volume of 20μL.  The reaction mixtures
were placed in an incubator at 37°C for 1hr.
2.2.1.2 Electrophoresis of DNA and purification from an agarose gel
DNA fragments were visualised by separation on an agarose based gel. 0.75% w/v
agarose gels were used throughout this thesis for DNA purification and analysis. The
required weight of agarose was added to TAE buffer (1mM EDTA, 40mM Tris-
Acetate, pH 7.0) and heated in order to dissolve the agarose. After cooling the
solution to approximately 50°C, Gel-Red dye supplied by Biotium was added in a
10,000x dilution. The liquid agarose solution was then poured into a mould containing
a well-forming comb and left at room temperature so that it could solidify. 6 x DNA
loading buffer supplied by Fermentas was mixed with the DNA samples and they
were loaded into the wells in the gel. The samples were then electrophoresed at 100V
in TAE buffer to achieve separation. 1kb Gene Ruler standard molecular weight
markers from Fermentas were utilised on the gel to ascertain the sizes of the various
fragments. After electrophoresis, the DNA was observed by exposing the gel to long-
wave UV light. Purification of the requisite DNA fragments from the gel was
performed by excising the bands of interest and using manufacturer’s gel extraction
kits to obtain the DNA.
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2.2.1.3 DNA Ligation
A rapid DNA ligation kit from Fermentas was used to ligate DNA fragments to
linearised vector. In order to reduce the risk of self-ligation of the plasmids, at least a
1:3 molar ratio of vector:insert was utilised in the ligation reactions. The reactions
were conducted at room temperature using 1μL of T4 DNA Ligase and 5μL of Rapid
Ligation Buffer in a total reaction volume of 20μL. The reaction mixture was stored
in the fridge until it was used for transformation.
2.2.1.4 Transformation and Growth of Bacteria
E.Coli XL-1 competent cells (obtained from Stratagene) that were stored at -80°C
were thawed on ice and 50μL of bacterial suspension was mixed with 5μL of ligated
plasmid reaction mix in 14mL BD Falcon polypropylene round-bottomed tubes. The
mixture was then incubated on ice for 30 minutes. The cells were then subjected to
heat-shock in a water bath at 42°C for 45 seconds, and then placed on ice for 2
minutes. 1mL of preheated LB media (42°C) was then added to the bacterial
suspension and the tubes were incubated at 37°C for 1 hour with shaking at 225rpm.
50μL of this cellular suspension was then added to 200μL of LB media and spread on
a selective agar plate. The plate was then placed overnight in an incubator at 37°C.
Amplification of positively transformed bacteria was achieved by inoculating a
bacterial colony from a selective agar plate into the requisite volume of LB media
with antibiotic. The tubes were then placed in a shaker at 37°C overnight with shaking
at 225rpm.
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2.2.1.5 Purification of Plasmid DNA
Plasmid DNA was purified from bacterial suspension using the Promega PureYield
Plasmid Miniprep System. In essence, cells in 3mL of bacterial culture were lysed by
the addition of lysis buffer. The mixture was then neutralised with neutralisation
solution. The bacterial cultures were then centrifuged at 13,000rpm for 3 minutes and
the supernatant was transferred to a Minicolumn which would bind the plasmid DNA.
The minicolumns were then washed and centrifuged to remove contaminants, and the
DNA was eluted with water. The purity and concentration of the purified plasmid
DNA was analysed by loading onto an agarose gel alongside a MW marker (1kb
GeneRuler, Fermentas).
2.2.1.6 PCR Site-Directed Mutagenesis
Unfortunately, mTORβWT was not cloned into the pcDNA3.1(+) vector using the
XhoI and NotI restriction enzymes. Therefore, it was not possible to excise it from its
original vector and directly clone it into the TAP-tag plasmid pCeMM-NTAP(GS). As
a result, primers were designed that would allow the XhoI and NotI restriction
sequences to be artificially introduced at the N and C termini of mTORβ respectively
by PCR. PCR reactions were carried out under different experimental conditions in
order to find the set of conditions that would generate the most PCR product. The
variables involved performing reactions either with or without DMSO. Furthermore,
for the PCR reactions that were performed with DMSO, three different annealing
temperatures were utilised. The PCR product would then be cloned into the pCeMM-
NTAP(GS) TAP tag vector.
PCR site-directed mutagenesis was also used to introduce the S2215Y and
12del mutations into mTORβ DNA. Forward and reverse oligonucleotide primers
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were designed for the S2215Y mutation and for the 12del mutation. Stratagene’s
QuikChange Site-Directed Mutagenesis Kit was used to create the required mutations
in the mTORα and mTORβ plasmids. The manufacturer’s manual can be viewed via
the following link:
http://www.genomics.agilent.com/files/Manual/200516.pdf
However, some modifications were made to the PCR reaction mixture on p10 of the
protocol. These included using 50ng of the mTORβ/pCDNA3.1(+) dsDNA template,
and an oligonucleotide primer concentration of 50ng/μL.
For the PCR reactions with 5% DMSO the following reaction volumes and conditions
were used:
Reaction Mixture (For 5% DMSO rxns):
Component Amount per reaction
dH2O 31μL
10x PfuUltra2 Reaction Buffer 5μL
50% DMSO 5μL
dNTP mix (2mM each dNTP) 5μL
DNA template (mTORB/pcDNA3.1(+)) (25ng/μL) 1μL
Primer #1 (10μM) 1μL
Primer #2 (10μM) 1μL
PfuUltra 2 fusion HS DNA Polymerase 1μL
Total Rxn Volume 50μL
PCR Cycling Parameters (For 5% DMSO rxns):
Segment No. of Cycles Temperature (°C) Duration
1 1 98°C 2mins
98°C 20s
60/62/64°C 20s2 30 cycles
72°C 1min
3 1 72°C 3mins
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For the PCR reactions without DMSO the following reaction volumes and conditions
were used:
Reaction Mixture (No DMSO):
Component Amount per reaction
dH2O 36μL
10x PfuUltra2 Reaction Buffer 5μL
dNTP mix (2mM each dNTP) 5μL
DNA template (mTORB/pcDNA3.1(+)) (25ng/μL) 1μL
Primer #1 (10μM) 1μL
Primer #2 (10μM) 1μL
PfuUltra 2 fusion HS DNA Polymerase 1μL
Total Rxn Volume 50μL
PCR Cycling Parameters (No DMSO):
Segment No. of Cycles Temperature (°C) Duration
1 1 95°C 2mins
95°C 20s
62°C 20s2 30 cycles
72°C 60s (15s per kb for targets > 1kb)
3 1 72°C 3mins
2.2.1.7 Purification of PCR product using Ethanol Precipitation
1/10 volume of 3M sodium acetate and 2 volumes of 100% ice-cold ethanol were
added to the PCR product sample tubes. The tubes were then cooled on dry ice for
20mins. The tubes were then centrifuged at max speed for 10mins. The supernatant
was decanted and the pellet was carefully washed with 100μL of 75% ice-cold ethanol.
The pellet was then dried by aspiration and the DNA was dissolved in 20μL of ddH2O.
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2.2.2 Mammalian Cell Culture and Methodology
2.2.2.1 Maintenance of Cell Lines
HEK293 cells were maintained in Dulbecco’s Modified Eagle’s medium (DMEM
from PAA) supplemented with 10% v/v foetal bovine serum (FBS from Hyclone) and
1% penicillin/streptomycin v/v antibiotics. Cells were grown in 37C̊ humidified
incubators at 10% CO2. When cells had reached 60-80% confluency, they were
passaged. The medium was aspirated and the cells were washed with 1 x Dulbecco’s
phosphate buffered saline (PBS from PAA). The cells were then detached from the
plates by the addition of trypsin-EDTA (supplied by PAA). The plates were then
placed in the incubators at 37C̊ for 1-2 minutes in order to fully detach the cells. Fresh
medium was then added to neutralise the trypsin and the cellular suspension was
pipetted up and down continuously to break up any clumps of cells. The volume of
cellular suspension required to achieve a desired ratio was then added into new plates
containing fresh medium. Subculturing was conducted in a laminar flow hood, which
was totally sterile with media and reagents that had been previously pre-warmed to
37C̊.
2.2.2.2 Transient Transfection of HEK293 with plasmid DNA
When a 10cm plate had reached 80% confluency it was split (1/3) into three new
10cm plates with 8mL of fresh DMEM complete medium. 24hrs later, the media was
aspirated and 10mL of new DMEM complete medium was added to each plate. 10μg
of plasmid DNA was then mixed with 200μL of sterile 150mM NaCl. The DNA and
NaCl were mixed very well by pipette action. 35μL of Exgen500 transfection reagent
supplied by Fermentas was then added and the solution was immediately mixed by
pipette action for 10secs. The tubes were then incubated at room temperature for
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10mins before being added drop wise to the previously prepared plates of HEK293
cells with refreshed medium. The transfected cells were then placed in an incubator at
37C̊ for 48 hours before being they were frozen at -80C̊ or used for analysis.
2.2.2.3 Serum and Nutrient Starvation of cells and subsequent Stimulation
24hrs after transient transfection, the complete DMEM medium was aspirated and
was replaced with serum-free DMEM medium. The cells were then incubated at 37°C
overnight in this medium. The next morning, the serum-free media was removed and
the PBS was introduced into the plates. The cells were then incubated at 37°C for 1hr
to achieve nutrient starvation. At this point, the cells were either frozen at -80°C or
used for analysis.
In the latter set of experiments involving starvation followed by stimulation,
the conditions were altered slightly, but the methods employed were identical. Firstly,
the duration of serum starvation was extended to 24 hours. In addition, the cells were
subjected to nutrient deprivation for 3 hours rather than one. Stimulation was effected
by removing the PBS and incubating the cells in DMEM complete medium for 1hr at
37°C. The cells were then utilised for analysis for frozen at -80°C.
2.2.3 Isolation and analysis of proteins from HEK293 cells
2.2.3.1 Isolation of protein in total cell lysate from cultured HEK239 cells
The plates were removed from the incubator and the medium was aspirated. The cells
were washed with ice-cold PBS and placed on ice. The PBS was then aspirated and
the cells were lysed on ice with ice-cold lysis buffer (150mM NaCl, 1% Triton X-100,
50mM NaF, 20mM Tris-HCl pH 7.5 and Roche Protease inhibitor cocktail) for 20
minutes. The cell lysates were scraped from the plates and were placed in
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microcentrifuge tubes. The tubes were then centrifuged at maximum speed
(14,000rpm at 4°C) for 20mins in order to pellet the insoluble fraction. The
supernatants were then transferred to new tubes and the protein concentration of each
sample was ascertained by the Bradford assay.
2.2.3.2 Measuring Protein Concentration
The Bradford Assay was utilised to measure the protein concentration in each
sample’s soluble fraction. Bio-Rad Protein Assay Reagent was diluted 5x with ddH2O
to generate the working solution. Samples were made up by adding 1μL of each
sample to 1mL of diluted reagent solution. Measurements were made with a Bio-
photometer (supplied by Eppendorf) at an absorbance of 595nm utilising lcm plastic
cuvettes. The photometer generates results in the form of a curve on a graph of
concentration against absorbance. In addition, all measurements are calculated based
on standards provided in the preset.
2.2.3.3 Affinity Purification
Affinity purification was utilised to purify mTORβ/pCeMM-NTAP(GS) from the
soluble fraction of transiently transfected HEK293 cells. For each sample, 50μL of
Millipore PureProteome Protein G magnetic bead suspension was pipetted into a new
microcentrifuge tube. The tube was then placed in a magnetic rack and the storage
buffer was carefully removed with a pipette. 500μL of PBS containing 0.1% Tween
20 was then added to the beads and the tubes were vortexed vigorously for 20secs.
The tubes were then replaced in the magnetic stand and the PBS was removed with a
pipette. The soluble fractions of the HEK293 total cell lysates were then added to the
tubes. The tubes were then placed on a loop at 4°C for 2hrs. At the end of this time
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the tubes were placed in the magnetic rack and the beads were washed 3x with 500μL
PBS containing 0.1% Tween 20 per wash. 50μL Laemmli sample buffer was then
added to each sample tube, and the samples were mixed by vortexing. The tubes were
then boiled in a heat block at 100°C for 8mins and then centrifuged at 13,300rpm in a
desktop microcentrifuge for 10secs to collect any condensation. The samples were
then loaded onto a SDS-PAGE gel and electrophoresed, or frozen at -20°C for later
use.
2.2.3.4 Immunoprecipitation
Immunoprecipitation of particular proteins was achieved by using antibodies that
were specific for the protein of interest. Antibody was added to Protein A sepharose
beads followed by the total cell lysate in a microcentrifuge tube. The sample tubes
were then placed on a rotating wheel for 2hrs at 4°C. Following incubation on the
wheel, the tubes were washed 3x with extraction buffer containing protease inhibitors.
15μL of 2xSDS loading buffer was then added to the beads, and the mixture was
boiled for 8mins. The tubes were then centrifuged at max speed for 10secs in a
desktop centrifuge to collect condensation. The liquid component was then loaded
onto a SDS-PAGE gel.
2.2.3.5 SDS-PAGE
When one boils a protein sample with Laemmlli sample buffer, the SDS detergent
present in the buffer binds to the proteins. This results in the linearisation of the
protein as well as the formation of a uniform negative charge across the length of the
protein. Consequently, the protein samples can be separated by an electric current on
the basis of size. During electrophoresis, movement of the larger proteins is physically
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retarded by the matrix, whilst smaller proteins meet with less opposition and move
further more quickly. This has the effect of separation by size.
5x Laemmlli sample buffer (10%SDS, 250mM Tris pH6.8, 50% glycerol,
0.5% bromophenol blue, 50mM DTT) was added to protein samples in order to obtain
a final concentration of 1x. The samples were then boiled for 8 minutes in a heat
block at 100°C and centrifuged briefly at 3,000rpm before they were loaded onto the
polyacrylamide gel. 1mm thick NuPAGE 10% Bis-Tris gel with 10 wells were used in
conjunction with Invitrogen’s XCell SureLock Mini-Cell system. 20μL of sample was
loaded into each well as required. The gel was run with 1x MOPS SDS running buffer
(50mM MOPS, 50mM Tris Base, 0.1% SDS, 1mM EDTA, pH7.7) for 50mins at a
constant voltage of 200V.
2.2.3.6 Western Blotting
After separation of the proteins by size on a SDS-PAGE gel using electrophoresis, the
proteins were transferred from the gels using semi-dry transfer. The Trans-BlotTM
system (Biorad) was utilised to perform the semi-dry transfer. Once the gel cassette
was opened, superfluous parts of the gel were cut off and the gel was placed on a
sheet of PVDF membrane. The membrane and gel were sandwiched between four
sheets of pre-soaked 3MM filter paper and air bubbles were removed. Transfer was
then conducted at a constant current of 0.3mA for 1 hour.
Following transfer, membranes were washed with TBST (10mM Tris-HCl
pH7.5, 150mM NaCl, 0.1% Tween 20) before they were blocked for 1 hour in TBST
containing 5% (w/v) non-fat dried milk powder. Blocking seeks to minimise non-
specific binding of the antibodies to the membrane. Primary antibodies were diluted
according to the manufacturer’s guidelines in TBST containing 2% BSA and 0.02%
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sodium azide. The membranes were then incubated with the primary antibody
solutions overnight at 4°C. The following morning, the membranes were washed 3
times for 10mins per wash in fresh TBST buffer. The membranes were then incubated
for 1 hour at room temperature with the relevant HRP-linked secondary antibody,
which was diluted in TBST with 5% milk powder. TBST was then used to wash the
membranes 3 times, 10mins per wash prior to development by enhanced
chemiluminescence (ECL).
Equal volumes of ECL solution 1 (coumaric acid, luminol, 50mM Tris-HCl)
and ECL solution 2 (0.02% H2O2, 50mM Tris-HCl) were mixed and incubated with
the membrane for 1 and a half minutes at room temperature. The membrane was then
encased in Saran wrap and excess ECL solution was removed by blotting. The bands
were then visualised by exposing the membrane to an X-ray film in a dark room for
different durations.
2.2.3.7 Table of all antibodies used
Antibody Product Code Manufacturer/Source Dilution used
Anti-Actin - Produced by former student 1 to 1000
Anti-Myc - Produced by former student 1 to 1000
Anti-EE - Produced by former student 1 to 1000
Anti-Akt #9272 Cell Signalling 1 to 1000
Anti-PAkt #4051 Cell Signalling 1 to 1000
Anti-4E-BP1 #9452 Cell Signalling 1 to 1000
Anti-P4E-BP1 #2855 Cell Signalling 1 to 1000
Anti-S6K1 ab32359 Abcam 1 to 1000
Anti-S6K1 (Phospho T389) ab2571 Abcam 1 to 1000
Anti-PmTOR (Ser2448) 09-213 Millipore 1 to 1000
Anti-mTOR 07-231 Millipore 1 to 1000
Anti-Rabbit Secondary AB W4011 Promega 1 to 5000
Anti-Mouse Secondary AB W4021 Promega 1 to 5000
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2.3 Bioinformatics methods
2.3.1 Comparative Modelling
The basis of comparative modelling rests on the principle that the crystal or NMR
structure of a protein can be used as a template to model another homologous protein.
The Protein Data Bank was searched using BLAST (Altschul et al. 1997) with the
amino acid sequence of mTOR’s kinase domain. The search produced a list of
proteins that shared a significant degree of sequence similarity with mTOR’s kinase
domain. From the list, the protein that had the best combination of percentage
sequence identity, e-value and query coverage was selected to be the template protein.
This was the crystal structure of PI3Kδ (PDB Cod e: 2X38) (Berndt et al. 2010) .
The alignment produced by BLAST between mTOR’s kinase domain and
PI3Kδ was then annotated with PI3Kδ’s secondary structure. This was obtained from
DSSP (Kabsch & Sander 1983) on the EBI website. The initial BLAST alignment was
then manually amended to produce a more likely structural alignment; for example
moving indels in the middle of secondary structure elements into adjacent loop
regions. The individual amendments are described in detail in results chapter 1.
BLAST did not align the entire length of mTOR’s kinase domain with PI3Kδ.
The alignment was therefore extended to include the C-terminal and N-terminal
regions that had initially been omitted. This was done by firstly converting the mTOR
sequence into PIR format. Then, PI3Kδ’s kinase domain was edited out of the PDB
file (2X38) and the sequence was extracted in PIR format. The two sequences were
then aligned in their entirety using Andrew Martin’s Needleman and Wunsch
(Needleman & Wunsch 1970) alignment program (nw). The terminal regions not
present in the initial BLAST alignment were extracted from this new alignment and
appended to the amended BLAST alignment.
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A linker region joins the FRB and Kinase domains in mTORβ. The alignment
between mTOR’s linker and PI3Kγ  in (Sturgill & Hall 2009) was copied. This was
then annotated with PI3Kγ’s secondary structure, which was obtained from DSSP at
the EBI website. The position of one indel in the sequence alignment was altered in
order to improve the alignment in structural terms.
Dr Andrew Martin’s ProFit programme (Martin and Porter,
http://www.bioinf.org.uk/software/profit/) was used to superimpose PI3Kδ onto
PI3Kγ using the McLachlan algorithm, (McLachlan, 1982). This provided a reference
point from which one could later position mTORβ’s FRB, Kinase and linker domains
relative to each other in a multiple alignment. Using the text editor Emacs, the PDB
files for PI3Kδ (2X38), (Berndt et al. 2010)  and PI3Kγ (1E8X), (Walker et al. 2000)
were both trimmed down to their kinase domains. Starting from a sequence alignment,
ProFit was used in iterative mode to align the two structures allowing Cα pairs to be
considered if they were up to 10Å apart. This created a structural alignment,
superimposing the structure for PI3Kδ onto the structure for PI3Kγ.
A multiple alignment was then generated between mTOR, FRB and PI3Kγ
and PI3Kδ in PIR format (see Fig. 11 in results chapter 1). A MODELLER control
file was created to read the sequence alignment file and use PDB files for PI3Kδ
(2X38_A), PI3Kγ (1E8X_A)  and FRB (2GAQ_A) in standard homology modelling
mode. MODELLER (Sali & Overington 1994) was then run to produce a 3D model of
mTOR’s kinase domain and the structure was viewed using RASMOL (Sayle &
Milner-White 1995).
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Chapter 3: Results
Comparative Modelling of
mTORβ’s kinase domain
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Chapter 3: Comparative Modelling of mTORβ’s
kinase domain
3.0) Introduction
To date no 3D structures of mTOR or its kinase domain have been generated by either
X-ray crystallography or NMR. However, cryo-EM structures of mTORC1 (Yip et al.
2010) as well as TOR and its complex with KOG1 (Adami et al. 2007) have been
elucidated. Although models produced utilising these methods can be more accurate,
the time and expense that are required by these techniques has led to the use of in
silico techniques. A model for the catalytic region of TOR has already been generated
by the comparative modelling approach using PI3Kγ as the homologue (Sturgill &
Hall 2009). The principle of homology modelling is based on the idea that a protein of
known structure can be used as the template to produce a model for a homologous
protein. The accuracy of the resultant 3D structure generated increases with the higher
degree of sequence similarity between the two proteins. Comparative modelling was
used to generate a model of mTOR’s kinase domain using PI3Kδ as the template. A
BLAST search of the PDB showed that PI3Kδ’s kinase domain possessed 28%
sequence identity with the kinase domain of mTOR, whereas PI3Kγ only shared 21%.
Therefore, using PI3Kδ (2X38)  as the template should result in a more accurate
model. A NMR structure of mTOR’s FRB domain already exists (Leone et al. 2006).
Rapamycin and rapalogues, which mimic its inhibitory action, bind to mTOR via the
FRB domain when in complex with FKBP12. The goal was to produce a model of
mTOR’s kinase domain and then to link this with the NMR model of the FRB domain.
The model produced would potentially help us to understand possible mechanisms by
which rapamycin and ATP-competitive inhibitors act on mTOR. Aside from gaining
experience and knowledge of molecular modelling using bioinformatics, it was also
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hoped that the model would provide useful insights into the mechanisms of mTOR
regulation and would help mTOR inhibitor studies in the group.
Results
3.1) Protein BLAST of PDB and annotation of alignment with secondary
structure
A protein BLAST search of the PDB was performed using the amino acid sequence of
mTORβ’s kinase domain as the query sequence. From the list of proteins generated, it
was observed that PI3Kδ (2X38), (Berndt et al. 2010) was the best homologue for
mTOR’s kinase domain. This was due to the fact that it possessed the highest
percentage sequence identity (28%). PI3Kδ also had an E-value of 3x10-12, and an e-
value ≤ 0.02 implies that the sequences are probably homologous. Therefore it is very
likely that PI3Kδ is a homologue for mTOR’s kinase domain. The alignment between
PI3Kδ and mTOR Kinase produced by BLAST was annotated with PI3Kδ’s
secondary structure. The secondary structure data for PI3Kδ were obtained from
DSSP (Kabsch & Sander 1983) on the EBI website. This can be seen in Fig. 3.1.
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mTORβ  23   GSNGHEFVFLLKGHEDLRQDERVMQLFGLVNTLLANDPTSLRKNLSIQRYAVIPLSTNSG  82
GS G+  + + K  +DLRQD   +Q+  L++ L   +   LR    +  Y  +P    +G
PI3Kδ  769  GSAGNVGI-IFKNGDDLRQDMLTLQMIQLMDVLWKQEGLDLR----MTPYGCLPTGDRTG  823
2° Struc ####.EEE-EEEE##..HHHHHHHHHHHHHHHHHHH##....----.....EEEEE..EE
mTORβ  83   LIGWVPHCDTLHALIRDYREKKKILLNIEHRIMLRMAPDYDHLTLMQKVEVFEHAVNNTA  142
LI  V H DT+            I LN  +     MA                      A
PI3Kδ  824 LIEVVLHSDTI----------ANIQLNKSN-----MAA-------------------TAA  849
2° Struc    EEE...#EEEH----------HHHH#..##-----###-------------------..#
mTORβ  143  GDDLAKLLWLKSPSSEVWFDRR-TNYTRSLAVMSMVGYILGLGDRHPSNLMLDRLSGKIL  201
+  A L WLKS +     DR +T S A   +  Y+LG+GDRH  N+M+ R SG++
PI3Kδ  850  FNKDALLNWLKSKNPGEALDRAIEEFTLSCAGYCVATYVLGIGDRHSDNIMI-RESGQLF  908
2° Struc ####HHHHHHHHH#.##HHHHHHHHHHHHHHHHHHHHHHH#.....###EEE-E###.EE
mTORβ  202  HIDFGDCFEVAMTREKFP---EKIPFRLTRMLTNAMEVTGLDGN-----YRITCHTVMEV  253
HIDFG    +   + KF    E++PF LT    + ++    + +     +R  C     +
PI3Kδ  909  HIDFGHF--LGNFKTKFGINRERVPFILTYDFVHVIQQGKTNNSEKFERFRGYCERAYTI  966
2° Struc    E......--##..!!!!!!!!!.......HHHHHHH###.#..HHHHHHHHHHHHHHHHH
mTORβ  254  LREH  257
LR H
PI3Kδ  967  LRRH  970
2° Struc HHH#
Legend  (The same legend has been used in all the following figures)
E = extended strand, participates in β-ladder
H = 4-helix (α-helix)
- = insertion in mTORβ with respect to PI3Kδ
. = no secondary structure has been defined at this location (i.e. coil)
# = secondary structure other than an alpha-helix or extended strand (i.e. 3-helix (G),
bend (S) or residue in isolated β-bridge (B))
! = region of unknown amino acid sequence
+ = conservative substitution
2° Struc = Protein secondary structure annotation
Fig. 3.1, BLAST alignment between mTORβ Kinase and PI3Kδ. PI3Kδ has been
annotated with its secondary structure, which was obtained from the DSSP in the EBI
website.
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3.2) Amending the BLAST alignment between mTORβ Kinase and PI3Kδ to
produce a structural alignment
The sequence alignment produced by BLAST between mTORβ kinase and PI3Kδ
was manually amended. This sought to achieve a far more plausible structural
alignment between the two proteins which would ultimately result in a more accurate
model. The reason(s) behind each of the changes are described below:
(a) The presence of an indel in the middle of the beta strand that stretched from
residues 774-780 in the PI3Kδ line was not structurally viable, so it was moved to the
start of the N-terminus. It was not moved into the loop region in the C-terminal
direction because it would have been undesirable to disrupt the relatively higher
sequence identity between the two proteins in that region. See Fig. 3.2A and 3.2B.
(b) The position of the insertion was checked in Ramsol, and it was decided that the 4
indels (b) should be shifted one position to the right by moving M810 in PI3Kδ’s
sequence one place to the left. This sought to minimise structural clashes (i.e.
insertion clashing with other secondary structure elements). See Fig. 3.3A and 3.3B.
(c) The BLAST alignment positioned loop regions of 5 and 19 residues in length
either side of the undefined, small piece of secondary structure defined by the 3
residues MAA (PI3Kδ line, residues 844-846). It was thought to be far more logical to
coalesce these loop regions since they will be poorly modelled anyway. See Fig. 3.4A
and 3.4B.
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(d) The indel in the middle of the beta strand at position 901 in PI3Kδ’s sequence was
moved one position to the right into the adjacent loop region, where indels are usually
found. See Fig. 3.5A and 3.5B.
(e) The deleted residues (238-242) in the mTORβ line (951-955 in PI3Kδ line) were
moved 7 residue positions to the left. This was prudent in terms of a structural
alignment because it was far better to have a deletion in a loop region rather than in an
α-helix.  The N242 amino acid was connected to the Y243 residue, which is part of an
α-helix. This was because it was structurally unfavourable to have a single residue
long piece of α-helix existing in isolation. See Fig. 3.6A and 3.6B.
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mTORβ  23   GSNGHEFVFLLKGHEDLRQDERVMQLFGLVNTLLANDPTSLRKNLSIQRYAVIPLSTNSG  82
GS G+  + + K  +DLRQD   +Q+  L++ L   +   LR    +  Y  +P    +G
PI3Kδ  769  GSAGNVGI-IFKNGDDLRQDMLTLQMIQLMDVLWKQEGLDLR----MTPYGCLPTGDRTG  823
2° Struc ####.EEE-EEEE##..HHHHHHHHHHHHHHHHHHH##....----.....EEEEE..EE
(a)
mTORβ  83   LIGWVPHCDTLHALIRDYREKKKILLNIEHRIMLRMAPDYDHLTLMQKVEVFEHAVNNTA  142
LI  V H DT+            I LN +     MA                      A
PI3Kδ  824  LIEVVLHSDTI----------ANIQLNKSN-----MAA-------------------TAA  849
2° Struc    EEE...#EEEH----------HHHH#..##-----###-------------------..#
mTORβ  143  GDDLAKLLWLKSPSSEVWFDRR-TNYTRSLAVMSMVGYILGLGDRHPSNLMLDRLSGKIL  201
+  A L WLKS +     DR    +T S A   +  Y+LG+GDRH  N+M+ R SG++
PI3Kδ  850  FNKDALLNWLKSKNPGEALDRAIEEFTLSCAGYCVATYVLGIGDRHSDNIMI-RESGQLF  908
2° Struc    ####HHHHHHHHH#.##HHHHHHHHHHHHHHHHHHHHHHH#.....###EEE-E###.EE
mTORβ  202  HIDFGDCFEVAMTREKFP---EKIPFRLTRMLTNAMEVTGLDGN-----YRITCHTVMEV  253
HIDFG    +   + KF    E++PF LT    + ++    + +     +R  C     +
PI3Kδ  909  HIDFGHF--LGNFKTKFGINRERVPFILTYDFVHVIQQGKTNNSEKFERFRGYCERAYTI  966
2° Struc    E......--##..!!!!!!!!!.......HHHHHHH###.#..HHHHHHHHHHHHHHHHH
mTORβ  254  LREH  257
LR H
PI3Kδ  967  LRRH  970
2° Struc HHH#
Fig. 3.2A, Location of first change to the initial BLAST alignment. The initial
position of the indel (a) has been highlighted yellow.
mTORβ 23   GSNGHEFVFLLKGHEDLRQDERVMQLFGLVNTLLANDPTSLRKNLSIQRYAVIPLSTNSG  82
++ + + + K  +DLRQD   +Q+  L++ L   +   LR    +  Y  +P    +G
PI3Kδ 769 -GSAGNVGIIFKNGDDLRQDMLTLQMIQLMDVLWKQEGLDLRM----TPYGCLPTGDRTG  823
2°Struc 769 -####.EEEEEEE##..HHHHHHHHHHHHHHHHHHH##.....----....EEEEE..EE  823
(a) (b)
mTORβ 83   LIGWVPHCDTLHALIRDYREKKKILLNIEHRIMLRMAPDYDHLTLMQKVEVFEHAVNNTA  142
LI  V H DT             I LN  + ++ A
PI3Kδ 824  LIEVVLHSDTI----------ANIQLNKSNMAA------------------------TAA  849
2°Struc 824  EEE...#EEEH----------HHHH#..#####------------------------..#  849
(c)
mTORβ 143  GDDLAKLLWLKSPSSEVWFDRR-TNYTRSLAVMSMVGYILGLGDRHPSNLMLDRLSGKIL  201
+  A L WLKS +     DR    +T S A   +  Y+LG+GDRH  N+M+   SG++
PI3Kδ 850  FNKDALLNWLKSKNPGEALDRAIEEFTLSCAGYCVATYVLGIGDRHSDNIMIR-ESGQLF  908
2°Struc 850  ####HHHHHHHHH#.##HHHHHHHHHHHHHHHHHHHHHHH#.....###EEEE-###.EE  908
(d)
(e)
mTORβ 202  HIDFGDCFEVAMTREKFP---EKIPFRLTRMLTNAME-----VTGLDGNYRITCHTVMEV  253
HIDFG    +   + KF    E++PF LT  + ++  +     +R  C     +
PI3Kδ 909  HIDFGHF--LGNFKTKFGINRERVPFILTYDFVHVIQQGKTNNSEKFERFRGYCERAYTI  966
2°Struc 909  E......--##..!!!!!!!!!.......HHHHHHH###.#..HHHHHHHHHHHHHHHHH  966
mTORβ 254  LREH  257
LR H
PI3Kδ 967  LRRH  970
2°Struc 967  HHH#  970
Fig. 3.2B, Amended BLAST alignment between mTORβ Kinase and PI3Kδ. The
indel that has been shifted from its original position has been highlighted blue in
PI3Kδ and red in the secondary structure annotation line. The change of interest has
been marked (a).
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mTORβ  23   GSNGHEFVFLLKGHEDLRQDERVMQLFGLVNTLLANDPTSLRKNLSIQRYAVIPLSTNSG  82
GS G+  + + K  +DLRQD   +Q+  L++ L   +   LR    +  Y  +P    +G
PI3Kδ  769  GSAGNVGI-IFKNGDDLRQDMLTLQMIQLMDVLWKQEGLDLR----MTPYGCLPTGDRTG  823
2° Struc ####.EEE-EEEE##..HHHHHHHHHHHHHHHHHHH##....----.....EEEEE..EE
(b)
mTORβ  83   LIGWVPHCDTLHALIRDYREKKKILLNIEHRIMLRMAPDYDHLTLMQKVEVFEHAVNNTA  142
LI  V H DT+            I LN  +     MA                      A
PI3Kδ  824  LIEVVLHSDTI----------ANIQLNKSN-----MAA-------------------TAA  849
2° Struc    EEE...#EEEH----------HHHH#..##-----###-------------------..#
mTORβ  143  GDDLAKLLWLKSPSSEVWFDRR-TNYTRSLAVMSMVGYILGLGDRHPSNLMLDRLSGKIL  201
+  A L WLKS +     DR    +T S A   +  Y+LG+GDRH  N+M+ R SG++
PI3Kδ  850 FNKDALLNWLKSKNPGEALDRAIEEFTLSCAGYCVATYVLGIGDRHSDNIMI-RESGQLF  908
2° Struc    ####HHHHHHHHH#.##HHHHHHHHHHHHHHHHHHHHHHH#.....###EEE-E###.EE
mTORβ  202  HIDFGDCFEVAMTREKFP---EKIPFRLTRMLTNAMEVTGLDGN-----YRITCHTVMEV  253
HIDFG    +   + KF    E++PF LT    + ++    + +     +R  C     +
PI3Kδ  909  HIDFGHF--LGNFKTKFGINRERVPFILTYDFVHVIQQGKTNNSEKFERFRGYCERAYTI  966
2° Struc    E......--##..!!!!!!!!!.......HHHHHHH###.#..HHHHHHHHHHHHHHHHH
mTORβ  254  LREH  257
LR H
PI3Kδ  967  LRRH  970
2° Struc HHH#
Fig. 3.3A, Location of second change to the initial BLAST alignment. The initial
positions of the indels and M810 residue (b) have been highlighted yellow.
mTORβ 23   GSNGHEFVFLLKGHEDLRQDERVMQLFGLVNTLLANDPTSLRKNLSIQRYAVIPLSTNSG  82
++ + + + K  +DLRQD   +Q+  L++ L   +   LR   Y  +P    +G
PI3Kδ 769 -GSAGNVGIIFKNGDDLRQDMLTLQMIQLMDVLWKQEGLDLRM----TPYGCLPTGDRTG  823
2°Struc 769 -####.EEEEEEE##..HHHHHHHHHHHHHHHHHHH##.....----....EEEEE..EE  823
(a) (b)
mTORβ 83   LIGWVPHCDTLHALIRDYREKKKILLNIEHRIMLRMAPDYDHLTLMQKVEVFEHAVNNTA  142
LI  V H DT      I LN  + ++ A
PI3Kδ 824  LIEVVLHSDTI----------ANIQLNKSNMAA------------------------TAA  849
2°Struc 824  EEE...#EEEH----------HHHH#..#####------------------------..#  849
(c)
mTORβ 143  GDDLAKLLWLKSPSSEVWFDRR-TNYTRSLAVMSMVGYILGLGDRHPSNLMLDRLSGKIL  201
+  A L WLKS +     DR    +T S A   +  Y+LG+GDRH  N+M+   SG++
PI3Kδ 850  FNKDALLNWLKSKNPGEALDRAIEEFTLSCAGYCVATYVLGIGDRHSDNIMIR-ESGQLF  908
2°Struc 850  ####HHHHHHHHH#.##HHHHHHHHHHHHHHHHHHHHHHH#.....###EEEE-###.EE  908
(d)
(e)
mTORβ 202  HIDFGDCFEVAMTREKFP---EKIPFRLTRMLTNAME-----VTGLDGNYRITCHTVMEV  253
HIDFG    +   + KF    E++PF LT    + ++  +     +R  C     +
PI3Kδ 909  HIDFGHF--LGNFKTKFGINRERVPFILTYDFVHVIQQGKTNNSEKFERFRGYCERAYTI  966
2°Struc 909  E......--##..!!!!!!!!!.......HHHHHHH###.#..HHHHHHHHHHHHHHHHH  966
mTORβ 254  LREH  257
LR H
PI3Kδ 967  LRRH  970
2°Struc 967  HHH#  970
Fig. 3.3B, Amended BLAST alignment between mTORβ Kinase and PI3Kδ. The
indels and residue that have been shifted from their original positions have been
highlighted blue in PI3Kδ and red in the secondary structure annotation line. The
change of interest has been marked (b).
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mTORβ  23   GSNGHEFVFLLKGHEDLRQDERVMQLFGLVNTLLANDPTSLRKNLSIQRYAVIPLSTNSG  82
GS G+  + + K  +DLRQD   +Q+ L++ L   +   LR    +  Y  +P    +G
PI3Kδ  769  GSAGNVGI-IFKNGDDLRQDMLTLQMIQLMDVLWKQEGLDLR----MTPYGCLPTGDRTG  823
2° Struc    ####.EEE-EEEE##..HHHHHHHHHHHHHHHHHHH##....----.....EEEEE..EE
mTORβ  83   LIGWVPHCDTLHALIRDYREKKKILLNIEHRIMLRMAPDYDHLTLMQKVEVFEHAVNNTA  142
LI  V H DT+            I LN  +     MA                      A
PI3Kδ  824  LIEVVLHSDTI----------ANIQLNKSN-----MAA-------------------TAA  849
2° Struc    EEE...#EEEH----------HHHH#..##-----###-------------------..#
(c)
mTORβ  143  GDDLAKLLWLKSPSSEVWFDRR-TNYTRSLAVMSMVGYILGLGDRHPSNLMLDRLSGKIL  201
+  A L WLKS +     DR    +T S A   +  Y+LG+GDRH  N+M+ R SG++
PI3Kδ  850  FNKDALLNWLKSKNPGEALDRAIEEFTLSCAGYCVATYVLGIGDRHSDNIMI-RESGQLF  908
2° Struc    ####HHHHHHHHH#.##HHHHHHHHHHHHHHHHHHHHHHH#.....###EEE-E###.EE
mTORβ  202  HIDFGDCFEVAMTREKFP---EKIPFRLTRMLTNAMEVTGLDGN-----YRITCHTVMEV  253
            HIDFG    +   + KF    E++PF LT    + ++    + +     +R  C     +
PI3Kδ  909  HIDFGHF--LGNFKTKFGINRERVPFILTYDFVHVIQQGKTNNSEKFERFRGYCERAYTI  966
2° Struc    E......--##..!!!!!!!!!.......HHHHHHH###.#..HHHHHHHHHHHHHHHHH
mTORβ  254  LREH  257
LR H
PI3Kδ  967  LRRH  970
2° Struc HHH#
Fig. 3.4A, Location of third change to the initial BLAST alignment. The initial
position of the indels and MAA residues (c) have been highlighted yellow.
mTORβ 23   GSNGHEFVFLLKGHEDLRQDERVMQLFGLVNTLLANDPTSLRKNLSIQRYAVIPLSTNSG  82
++ + + + K  +DLRQD   +Q+  L++ L   +   LR    +  Y  +P    +G
PI3Kδ 769 -GSAGNVGIIFKNGDDLRQDMLTLQMIQLMDVLWKQEGLDLRM----TPYGCLPTGDRTG  823
2°Struc 769 -####.EEEEEEE##..HHHHHHHHHHHHHHHHHHH##.....----....EEEEE..EE  823
(a) (b)
mTORβ 83   LIGWVPHCDTLHALIRDYREKKKILLNIEHRIMLRMAPDYDHLTLMQKVEVFEHAVNNTA  142
LI  V H DT             I LN  + ++ A
PI3Kδ 824  LIEVVLHSDTI----------ANIQLNKSNMAA------------------------TAA  849
2°Struc 824  EEE...#EEEH----------HHHH#..#####------------------------..#  849
(c)
mTORβ 143  GDDLAKLLWLKSPSSEVWFDRR-TNYTRSLAVMSMVGYILGLGDRHPSNLMLDRLSGKIL  201
+  A L WLKS +     DR    +T S A   +  Y+LG+GDRH  N+M+   SG++
PI3Kδ 850  FNKDALLNWLKSKNPGEALDRAIEEFTLSCAGYCVATYVLGIGDRHSDNIMIR-ESGQLF  908
2°Struc 850  ####HHHHHHHHH#.##HHHHHHHHHHHHHHHHHHHHHHH#.....###EEEE-###.EE  908
(d)
(e)
mTORβ 202  HIDFGDCFEVAMTREKFP---EKIPFRLTRMLTNAME-----VTGLDGNYRITCHTVMEV  253
HIDFG    +   + KF    E++PF LT    + ++  +  +R  C     +
PI3Kδ 909  HIDFGHF--LGNFKTKFGINRERVPFILTYDFVHVIQQGKTNNSEKFERFRGYCERAYTI  966
2°Struc 909  E......--##..!!!!!!!!!.......HHHHHHH###.#..HHHHHHHHHHHHHHHHH  966
mTORβ 254  LREH  257
LR H
PI3Kδ 967  LRRH  970
2°Struc 967  HHH# 970
Fig. 3.4B, Amended BLAST alignment between mTORβ Kinase and PI3Kδ. The
indels and residues that have been shifted from their original positions have been
highlighted blue in PI3Kδ and red in the secondary structure annotation line. The
change of interest has been marked (c).
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mTORβ  23   GSNGHEFVFLLKGHEDLRQDERVMQLFGLVNTLLANDPTSLRKNLSIQRYAVIPLSTNSG  82
GS G+  + + K  +DLRQD   +Q+  L++ L   +   LR    +  Y  +P    +G
PI3Kδ  769 GSAGNVGI-IFKNGDDLRQDMLTLQMIQLMDVLWKQEGLDLR----MTPYGCLPTGDRTG  823
2° Struc    ####.EEE-EEEE##..HHHHHHHHHHHHHHHHHHH##....----.....EEEEE..EE
mTORβ  83   LIGWVPHCDTLHALIRDYREKKKILLNIEHRIMLRMAPDYDHLTLMQKVEVFEHAVNNTA  142
LI  V H DT+            I LN  +     MA                      A
PI3Kδ  824  LIEVVLHSDTI----------ANIQLNKSN-----MAA-------------------TAA  849
2° Struc    EEE...#EEEH----------HHHH#..##-----###-------------------..#
mTORβ  143  GDDLAKLLWLKSPSSEVWFDRR-TNYTRSLAVMSMVGYILGLGDRHPSNLMLDRLSGKIL  201
+  A L WLKS +     DR    +T S A   +  Y+LG+GDRH  N+M+ R SG++
PI3Kδ  850  FNKDALLNWLKSKNPGEALDRAIEEFTLSCAGYCVATYVLGIGDRHSDNIMI-RESGQLF  908
2° Struc ####HHHHHHHHH#.##HHHHHHHHHHHHHHHHHHHHHHH#.....###EEE-E###.EE
(d)
mTORβ  202  HIDFGDCFEVAMTREKFP---EKIPFRLTRMLTNAMEVTGLDGN-----YRITCHTVMEV 253
HIDFG    +   + KF    E++PF LT    + ++    + +     +R  C     +
PI3Kδ  909  HIDFGHF--LGNFKTKFGINRERVPFILTYDFVHVIQQGKTNNSEKFERFRGYCERAYTI  966
2° Struc    E......--##..!!!!!!!!!.......HHHHHHH###.#..HHHHHHHHHHHHHHHHH
mTORβ  254  LREH  257
LR H
PI3Kδ  967  LRRH  970
2° Struc HHH#
Fig. 3.5A, Location of fourth change to the initial BLAST alignment. The initial
position of the indel at position 901 in PI3Kδ’s sequence (d) has been highlighted
yellow.
mTORβ 23   GSNGHEFVFLLKGHEDLRQDERVMQLFGLVNTLLANDPTSLRKNLSIQRYAVIPLSTNSG  82
++ + + + K  +DLRQD   +Q+  L++ L   +   LR    +  Y  +P    +G
PI3Kδ 769 -GSAGNVGIIFKNGDDLRQDMLTLQMIQLMDVLWKQEGLDLRM----TPYGCLPTGDRTG  823
2°Struc 769 -####.EEEEEEE##..HHHHHHHHHHHHHHHHHHH##.....----....EEEEE..EE  823
(a) (b)
mTORβ 83   LIGWVPHCDTLHALIRDYREKKKILLNIEHRIMLRMAPDYDHLTLMQKVEVFEHAVNNTA  142
LI  V H DT             I LN  + ++ A
PI3Kδ 824  LIEVVLHSDTI----------ANIQLNKSNMAA------------------------TAA  849
2°Struc 824  EEE...#EEEH----------HHHH#..#####------------------------..#  849
(c)
mTORβ 143  GDDLAKLLWLKSPSSEVWFDRR-TNYTRSLAVMSMVGYILGLGDRHPSNLMLDRLSGKIL  201
+  A L WLKS +     DR    +T S A   +  Y+LG+GDRH  N+M+   SG++
PI3Kδ 850  FNKDALLNWLKSKNPGEALDRAIEEFTLSCAGYCVATYVLGIGDRHSDNIMIR-ESGQLF  908
2°Struc 850  ####HHHHHHHHH#.##HHHHHHHHHHHHHHHHHHHHHHH#.....###EEEE-###.EE  908
(d)
(e)
mTORβ 202  HIDFGDCFEVAMTREKFP---EKIPFRLTRMLTNAME-----VTGLDGNYRITCHTVMEV  253
HIDFG    +   + KF    E++PF LT    + ++  +     +R  C     +
PI3Kδ 909  HIDFGHF--LGNFKTKFGINRERVPFILTYDFVHVIQQGKTNNSEKFERFRGYCERAYTI  966
2°Struc 909  E......--##--!!!!!!!!!.......HHHHHHH###.#..HHHHHHHHHHHHHHHHH  966
mTORβ 254  LREH  257
LR H
PI3Kδ 967  LRRH  970
2°Struc 967  HHH#  970
Fig. 3.5B, Amended BLAST alignment between mTORβ Kinase and PI3Kδ. The
indels that was shifted from its original positions has been highlighted blue in PI3Kδ
and red in the secondary structure annotation line. The change of interest has been
marked (d).
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mTORβ  23   GSNGHEFVFLLKGHEDLRQDERVMQLFGLVNTLLANDPTSLRKNLSIQRYAVIPLSTNSG  82
GS G+  + + K  +DLRQD   +Q+  L++ L   +   LR    +  Y  +P    +G
PI3Kδ  769  GSAGNVGI-IFKNGDDLRQDMLTLQMIQLMDVLWKQEGLDLR----MTPYGCLPTGDRTG  823
2° Struc    ####.EEE-EEEE##..HHHHHHHHHHHHHHHHHHH##....----.....EEEEE..EE
mTORβ  83   LIGWVPHCDTLHALIRDYREKKKILLNIEHRIMLRMAPDYDHLTLMQKVEVFEHAVNNTA  142
            LI  V H DT+            I LN  +     MA                    A
PI3Kδ  824  LIEVVLHSDTI----------ANIQLNKSN-----MAA-------------------TAA  849
2° Struc    EEE...#EEEH----------HHHH#..##-----###-------------------..#
mTORβ  143  GDDLAKLLWLKSPSSEVWFDRR-TNYTRSLAVMSMVGYILGLGDRHPSNLMLDRLSGKIL  201
             +  A L WLKS +     DR    +T S A   +  Y+LG+GDRH  N+M+ R SG++
PI3Kδ  850  FNKDALLNWLKSKNPGEALDRAIEEFTLSCAGYCVATYVLGIGDRHSDNIMI-RESGQLF  908
2° Struc    ####HHHHHHHHH#.##HHHHHHHHHHHHHHHHHHHHHHH#.....###EEE-E###.EE
(e)
mTORβ  202  HIDFGDCFEVAMTREKFP---EKIPFRLTRMLTNAMEVTGLDGN-----YRITCHTVMEV  253
HIDFG    +   + KF    E++PF LT    + ++    + +     +R  C     +
PI3Kδ  909  HIDFGHF--LGNFKTKFGINRERVPFILTYDFVHVIQQGKTNNSEKFERFRGYCERAYTI  966
2° Struc    E......--##..!!!!!!!!!.......HHHHHHH###.#..HHHHHHHHHHHHHHHHH
mTORβ  254  LREH  257
LR H
PI3Kδ  967  LRRH  970
2° Struc HHH#
Fig. 3.6A, Location of fifth change to the initial BLAST alignment. The initial
positions of the deletions and N amino acid residues have been highlighted yellow (e).
mTORβ 23   GSNGHEFVFLLKGHEDLRQDERVMQLFGLVNTLLANDPTSLRKNLSIQRYAVIPLSTNSG  82
++ + + + K  +DLRQD   +Q+  L++ L   +   LR    +  Y  +P    +G
PI3Kδ 769 -GSAGNVGIIFKNGDDLRQDMLTLQMIQLMDVLWKQEGLDLRM----TPYGCLPTGDRTG  823
2°Struc 769 -####.EEEEEEE##..HHHHHHHHHHHHHHHHHHH##.....----....EEEEE..EE  823
(a) (b)
mTORβ 83   LIGWVPHCDTLHALIRDYREKKKILLNIEHRIMLRMAPDYDHLTLMQKVEVFEHAVNNTA  142
LI  V H DT             I LN  + ++ A
PI3Kδ 824  LIEVVLHSDTI----------ANIQLNKSNMAA------------------------TAA  849
2°Struc 824  EEE...#EEEH----------HHHH#..#####------------------------..#  849
(c)
mTORβ 143  GDDLAKLLWLKSPSSEVWFDRR-TNYTRSLAVMSMVGYILGLGDRHPSNLMLDRLSGKIL  201
+  A L WLKS +     DR    +T S A   +  Y+LG+GDRH  N+M+   SG++
PI3Kδ 850  FNKDALLNWLKSKNPGEALDRAIEEFTLSCAGYCVATYVLGIGDRHSDNIMIR-ESGQLF  908
2°Struc 850  ####HHHHHHHHH#.##HHHHHHHHHHHHHHHHHHHHHHH#.....###EEEE-###.EE  908
(d)
(e)
mTORβ 202  HIDFGDCFEVAMTREKFP---EKIPFRLTRMLTNAME-----VTGLDGNYRITCHTVMEV  253
HIDFG    +   + KF    E++PF LT    + ++  +     +R  C     +
PI3Kδ 909  HIDFGHF--LGNFKTKFGINRERVPFILTYDFVHVIQQGKTNNSEKFERFRGYCERAYTI  966
2°Struc 909  E......--##--!!!!!!!!!.......HHHHHHH###.#..HHHHHHHHHHHHHHHHH  966
mTORβ 254  LREH  257
LR H
PI3Kδ 967  LRRH  970
2°Struc 967  HHH#  970
Fig. 3.6B, Amended BLAST alignment between mTORβ Kinase and PI3Kδ. The
deletions and N residue that were shifted from their original positions have been
coloured red in the mTORβ line. The change of interest has been marked (e).
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Change Identity Similarity
WT 28% 14%
a 27% 16%
b 27% 15%
c 27% 15%
d 26% 16%
e 26% 16%
Fig. 3.7, A table showing changes in percentage identity and similarity between
the amino acids in the alignment between mTORβ and PI3Kδ after each
alteration in the alignment was made.
3.3) Extending the alignment produced by BLAST between mTORβ Kinase and
PI3Kδ
The alignment produced between PI3Kδ and mTORβ Kinase produced by BLAST
did not cover the whole length of the mTORβ Kinase domain. Residues were omitted
and were not aligned at both the C-terminus and the N-terminus. Therefore, it was
necessary to extend this alignment to encompass the full length of mTORβ’s kinase
domain. To do this, the mTOR sequence was firstly converted into PIR format. Then,
PI3Kδ’s kinase domain was edited out of the PDB file (2X38) and the sequence was
extracted in PIR format. The two sequences were then aligned in their entirety using
Andrew Martin’s Needleman and Wunsch (Needleman & Wunsch 1970) (nw) align
program. The terminal regions not present in the alignment shown in Fig. 3.2B were
extracted from this new alignment and appended to the original alignment shown in
Fig. 3.2B. The full, extended alignment is shown in Fig. 3.8A, and the additional N-
terminal and C-terminal alignments that were appended to the BLAST alignment in
Fig. 3.2B are shown in Fig. 3.8B.
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PI3Kδ Kinase is sequence in top line (blue), and mTORβ Kinase is sequence in second line
(pink)
STHHMKVLMKQGEALSKLKALNDFVKVSSQKTTKPQTKEMMHMCMRQETYMEALSHLQSPLDPSTLLEEVCVEQCTFMDS
-----------------------------------------------------------------------------IQS
KMKPLWIMYSSEEA------ GSAGN-VGIIFKNGDDLRQDMLTLQMIQLMDVLWKQEGLDLR----MTPYGCLPTGDRTG
IAPSLQVITSKQRPRKLTLM GSNGHEFVFLLKGHEDLRQDERVMQLFGLVNTLLANDPTSLRKNLSIQRYAVIPLSTNSG
LIEVVLHSDTIA----------NIQLNKSN---MAATAAFNKDALLN---------------------WLKSKNPGEALD
LIGWVPHCDTLHALIRDYREKKKILLNIEHRIMLRMAPDYDHLTLMQKVEVFEHAVNNTAGDDLAKLLWLKSPSSEVWFD
RAIEEFTLSCAGYCVATYVLGIGDRHSDNIMI-RESGQLFHIDFGH-F-LGNFRVPFI--LTYDFVHVIQQGKTNNSEKF
RRTN-YTRSLAVMSMVGYILGLGDRHPSNLMLDRLSGKILHIDFGDCFEVAMTREKFPEKIPFRLTRMLTNAMEVTGLD-
ERFRGYCERAYTILRRH GLLFLHLFALMRAAGLPELSCSKDIQYLKDSLALGKTEEEALKHFRVKFNEALRESW
GNYRITCHTVMEVLREH KDSVMAVLEAFVYDPLLNWRL------------------------------------
Fig. 3.8A, Full alignment between mTOR Kinase and PI3Kδ. This was generated
using Dr Andrew Martin’s Needleman and Wunsch program. The alignment upstream
of the first solid dark blue line represents the extended N-terminal region that was
manually appended to the initial alignment produced by BLAST between PI3Kδ and
mTOR’s Kinase domain. The alignment downstream of the second solid dark blue
line adds the C-terminal portion of mTOR’s kinase domain that was omitted by the
BLAST programme. The alignment in between the two dark blue lines shows the
amended BLAST alignment shown in Fig. 3.2B.
Additional N-terminal alignment between PI3Kδ Kinase and mTORβ Kinase
mTORβ ------------------------------------------------------------
PI3Kδ   675 STHHMKVLMKQGEALSKLKALNDFVKVSSQKTTKPQTKEMMHMCMRQETYMEALSHLQSP  734
2°Struc 675 .HHHHHHHHHHHHHHHHHHHHHHHHHHHHHH..HHHHHHHHHHHH..HHHHHHH..EEE.  675
mTORβ   1 -----------------IQSIAPSLQVITSKQRPRKLTLM                       23
                             ++S +++L ++ S++
PI3Kδ   735 LDPSTLLEEVCVEQCTFMDSKMKPLWIMYSSEEA------                      768
2°Struc 735 .EEEEEE.EE.....EE.......EEEEEE..........                      768
Additional C-terminal alignment betweeen PI3Kδ Kinase and mTORβ Kinase
mTORβ   259 KDSVMAVLEAFVYDPLLNWRL------------------------------------   279
                + +  +     L + +
PI3Kδ   971 GLLFLHLFALMRAAGLPELSCSKDIQYLKDSLALGKTEEEALKHFRVKFNEALRESW  1027
2°Struc 971 HHHHHHHHHHH..........HHHHHHHHHH......HHHHHHHHHHHHHHHHHH..
Fig. 3.8B, The additional alignments that were generated between mTOR’s
kinase domain and PI3Kδ by Andrew Martin’s Needleman and Wunsch align
program.  For the sake of clarity, the extended alignments at the N and C termini
have been shown below separately.
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3.4) Aligning the linker between mTOR’s Kinase and FRB domains with PI3Kγ
A linker region joins the FRB and Kinase domains in mTORβ. The alignment
between mTOR’s linker and PI3Kγ  in Mike Hall’s paper (Sturgill & Hall 2009) was
copied. This was then annotated with PI3Kγ’s secondary structure, which was
obtained from DSSP at EBI’s website. The position of one indel in the sequence
alignment was altered in order to improve the alignment in structural terms. This can
be seen in Figs. 3.9 and 3.10. PI3Kγ (Walker et al. 2000) was used as the homologue
to model the linker.
Target Strand (mTORα)
(mTORα is sequence on top line and spans residues 2109-2159, i.e. 51 residues)
RRISKQLPQLTSLELQYVSPKLLMCRDLELAVPGTYD-PNQPIIRIQSIAP-S
 +  +  +   S ++     K  +++  +L +P ++  P +P++++  ++  +
IKSLSAEKYDVSSQVISQL-KQKLENLQNLNLPQSFRVPYDPGLKAGALVIEK
HHH.........HHHHHHH-HHHHHHHH.......EEE..EEEEEEEEE....
Parent Strand (PI3Kγ)
(PI3Kγ is sequence on bottom line and spans residues 749-800, i.e. 52 residues)
Fig. 3.9, Initial alignment of mTOR’s Linker with PI3Kγ. The red indel is its
initial position prior to amendment.
Target Strand (mTORα)
(mTORα is the sequence on the top line and spans residues 2109-2159, i.e. 51
residues)
RRISKQLPQLTSLELQYVSPKLLMCRDLELAVPGTYD-PNQPIIRIQSIAP-S
 +  +  +   S +    + K  +++  +L +P ++  P +P++++  ++  +
IKSLSAEKYDVS-SQVISQLKQKLENLQNLNLPQSFRVPYDPGLKAGALVIEK
HHH.........-HHHHHHHHHHHHHHH.......EEE..EEEEEEEEE....
Parent Strand (PI3Kγ)
(PI3Kγ is the sequence on the bottom line and spans residues 749-800, i.e. 52 residues)
Fig. 3.10, Amended alignment between mTOR’s Linker and PI3Kγ. The indel that
has been highlighted red was moved from the middle of the helix in Mike Hall’s
alignment to the N-terminal loop region.
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3.5) Fitting PI3Kδ Kinase onto PI3Kγ
Dr Andrew Martin’s ProFit programme (Martin, A.C.R. and Porter, C.T.,
http://www.bioinf.org.uk/software/profit/) was used to superimpose PI3Kδ onto
PI3Kγ using the McLachlan algorithm, (McLachlan, A.D., 1982). This provided a
reference point from which one could later position mTORβ’s FRB, Kinase and linker
domains relative to each other in a multiple alignment. Using the text editor Emacs,
the PDB files for PI3Kδ (2X38), (Berndt et al. 2010) and PI3Kγ (1E8X), (Walker et al.
2000) were both trimmed down to their kinase domains. ProFit was then used to align
the two structures so that no pair of aligned Cα atoms was more than 10Å apart. The
program created a structural alignment, whereby the structure for PI3Kδ was super-
imposed onto the structure for PI3Kγ.
3.6) Producing the multiple alignment between mTOR, FRB, PI3Kδ and PI3Kγ
The alignment between PI3Kγ and PI3Kδ was merged with the alignment between
PI3Kδ and mTOR. The alignment between the Linker and PI3Kγ was also introduced
into mTOR’s alignment (See Figs. 3.9 and 3.10 above). Since PI3Kγ does not have a
FRB domain, it could not be used as a homologue to model the position of the FRB
domain relative to the kinase domain. This problem was circumvented by retaining 6
residues from PI3Kγ’s helical domain to the N-terminus of PI3Kγ’s linker. The other
94 residues that were originally aligned with FRB in Hall and Sturgill’s paper were
then shifted in the C-terminal direction by 94 residue positions. 94 gaps were inserted
in the place of the helical residues. The FRB domain would then be aligned with the
start of this gap region. MODELLER would effectively see the 6-residues from
PI3Kγ’s helical domain as a structural anchor, and would join the FRB domain to the
linker. This would avoid FRB being fitted onto PI3Kγ’s helical domain. The 94
residue gap was maintained throughout the 4 sequences in the alignment. A simple
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block diagram illustrating how the different domains and proteins were aligned can be
seen in Fig. 3.11. The sequences were aligned in PIR format. The final alignment can
be seen in Fig. 3.12 and Fig. 3.13.
Fig. 3.11, Diagram showing the alignment of the different proteins in the final
multiple alignment. mTOR’s kinase domain was aligned and modelled on PI3Kδ’s
kinase domain. mTOR’s linker was aligned and modelled using the corresponding
sequence in PI3Kγ. A NMR structure for mTOR’s FRB domain has already been
elucidated. It was appended to the N-terminus of PI3Kγ’s linker via the 6 residue long
‘structural anchor’.
mTOR FRB to Kinase
PI3Kδ
(2X38) Kinase
A
nchor
LinkerPI3Kγ(1E8X) Kinase
Helical
FRBFRB(2GAQ)
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>P1;MTORBP
sequence::::::mTORBetaFRB_to_Kinase:HUMAN::
------------------------------------------------------------
----------------------------------ELIRVAILWHEMWHEGLEEASRLYFG
ERNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKYMKSGNVKDLTQA
WDLYYHVFRRISKQLPQLTSLELQYVSPKLLMCRDLELAVPGT-----------YD-PNQ
PIIRIQSIAPSLQVITSK--QRPRKLTLMGSNGHEFVFLLKGHEDLRQDERVMQLFGLVN
TLLANDPTSLRKNLSIQRYAVIPLSTNSGLIGWVPHCDTLHALIRDYREKKKILLNIEHR
IMLRMAPDYDHLTLMQKVEVFEHAVNNTAGDDLAKLLWLKSPSS-EVWFDRR-TNYTRSL
AVMSMVGYILGLGDRHPSNLMLDRLSGKILHIDFGDCFEVAMTREKFP---EKIPFRLTR
MLTNAME-----VTGLDGNYRITCHTVMEVLREHKDSVMAVLEAFVYDPLLNWRL*
>P1;2X38_A
structureX:2X38:742:A:991:A:PI3KDelta Kinase:MOUSE:2.20:0.240
------------------------------------------------------------
------------------------------------------------------------
------------------------------------------------------------
------------------------------------------------------EEVCVE
QCTFMDSKMKPLWIMYSS--EEA-------GSAGNVGIIFKNGDDLRQDMLTLQMIQLMD
VLWKQEGLDLRM----TPYGCLPTGDRTGLIEVVLHSDTI----------ANIQLNKSNM
AA------------------------TAAFNKDALLNWLKSKNP-GEALDRAIEEFTLSC
AGYCVATYVLGIGDRHSDNIMIR-ESGQLFHIDFGHF--LGNF---------RVPFILTY
DFVHVIQQGKTNNSEKFERFRGYCERAYTILRRHGLLFLHLFALMRAAGLPELSC*
>P1;1E8X_A
structureX:1E8X:655:A:1044:A:PI3KGamma from FRB to
Kinase:WILDBOAR:2.20:0.255
DVLHYLLQLVQAVKFEPYHDSALARFLLKRGLRNKRIGHFLFWFLRSEIAQSRHYQQRFA
VILEAYLRGCGTAMLHDFTQQVQVIDMLQKVTID--------------------------
------------------------------------------------------------
--------IKSLSAEKYDVS-SQVISQLKQKLENLQNLNLPQSFRVPYDPGLKAGALVIE
KCKVMASKKKPLWLEFKCADP-------TALSNETIGIIFKHGDDLRQDMLILQILRIME
SIWETESLDLCL----LPYGCISTGDKIGMIEIVKDATTI----------AKIQ--QSTV
GN------------------------TGAFKDEVLSHWLKEKCPIEEKFQAAVERFVYSC
AGYCVATFVLGIGDRHNDNIMIS-ETGNLFHIDFGH-----------------VPFVLTP
DFLFVMGTSGKKTSLHFQKFQDVCVKAYLALRHHTNLLIILFSMMLMTGMPQLTS*
>P1;2GAQ_A
structureN:2GAQ:1:A:100:A:NMR Structure of mTOR's FRB
domain:HUMAN:HUMAN:0.00:0.00
------------------------------------------------------------
----------------------------------ELIRVAILWHEMWHEGLEEASRLYFG
ERNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKYMKSGNVKDLTQA
WDLYYHVFRRISKQ----------------------------------------------
------------------------------------------------------------
------------------------------------------------------------
------------------------------------------------------------
------------------------------------------------------------
-------------------------------------------------------*
Fig. 3.12, Final Multiple Alignment between mTOR, FRB, PI3Kγ and PI3Kδ in
PIR format.
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------------------------------------------------------------ mTORBeta
------------------------------------------------------------ PI3KDelta
DVLHYLLQLVQAVKFEPYHDSALARFLLKRGLRNKRIGHFLFWFLRSEIAQSRHYQQRFA PI3KGamma
------------------------------------------------------------ FRB
----------------------------------ELIRVAILWHEMWHEGLEEASRLYFG mTORBeta
------------------------------------------------------------ PI3KDelta
VILEAYLRGCGTAMLHDFTQQVQVIDMLQKVTID-------------------------- PI3KGamma
----------------------------------ELIRVAILWHEMWHEGLEEASRLYFG FRB
ERNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKYMKSGNVKDLTQA mTORBeta
------------------------------------------------------------ PI3KDelta
------------------------------------------------------------ PI3KGamma
ERNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKYMKSGNVKDLTQA FRB
WDLYYHVFRRISKQLPQLTSLELQYVSPKLLMCRDLELAVPGT-----------YD-PNQ mTORBeta
------------------------------------------------------EEVCVE PI3KDelta
--------IKSLSAEKYDVS-SQVISQLKQKLENLQNLNLPQSFRVPYDPGLKAGALVIE PI3KGamma
WDLYYHVFRRISKQ---------------------------------------------- FRB
PIIRIQSIAPSLQVITSK--QRPRKLTLMGSNGHEFVFLLKGHEDLRQDERVMQLFGLVN mTORBeta
QCTFMDSKMKPLWIMYSS--EEA-------GSAGNVGIIFKNGDDLRQDMLTLQMIQLMD PI3KDelta
KCKVMASKKKPLWLEFKCADP-------TALSNETIGIIFKHGDDLRQDMLILQILRIME PI3KGamma
------------------------------------------------------------ FRB
TLLANDPTSLRKNLSIQRYAVIPLSTNSGLIGWVPHCDTLHALIRDYREKKKILLNIEHR mTORBeta
VLWKQEGLDLRM----TPYGCLPTGDRTGLIEVVLHSDTI----------ANIQLNKSNM PI3KDelta
SIWETESLDLCL----LPYGCISTGDKIGMIEIVKDATTI----------AKIQ--QSTV PI3KGamma
------------------------------------------------------------ FRB
IMLRMAPDYDHLTLMQKVEVFEHAVNNTAGDDLAKLLWLKSPSS-EVWFDRR-TNYTRSL mTORBeta
AA------------------------TAAFNKDALLNWLKSKNP-GEALDRAIEEFTLSC PI3KDelta
GN------------------------TGAFKDEVLSHWLKEKCPIEEKFQAAVERFVYSC PI3KGamma
------------------------------------------------------------ FRB
AVMSMVGYILGLGDRHPSNLMLDRLSGKILHIDFGDCFEVAMTREKFP---EKIPFRLTR mTORBeta
AGYCVATYVLGIGDRHSDNIMIR-ESGQLFHIDFGHF--LGNF---------RVPFILTY PI3KDelta
AGYCVATFVLGIGDRHNDNIMIS-ETGNLFHIDFGH-----------------VPFVLTP PI3KGamma
------------------------------------------------------------ FRB
MLTNAME-----VTGLDGNYRITCHTVMEVLREHKDSVMAVLEAFVYDPLLNWRL*     mTORBeta
DFVHVIQQGKTNNSEKFERFRGYCERAYTILRRHGLLFLHLFALMRAAGLPELSC*     PI3KDelta
DFLFVMGTSGKKTSLHFQKFQDVCVKAYLALRHHTNLLIILFSMMLMTGMPQLTS*     PI3KGamma
-------------------------------------------------------*     FRB
Fig 3.13, Final Multiple Alignment between mTOR, FRB, PI3Kγ and PI3Kδ in
block  format.
Structural and Functional Analysis of mTORβ
95
3.7) Modelling the final alignment
The multiple alignment (Fig. 3.12) took into account the fit that had been made
between PI3Kδ and PI3Kγ, as well ensuring that the alignment between PI3Kδ and
mTOR Kinase was preserved. MODELLER (Sali et al. 1995) was then used to
generate a model. The key residues in the ATP binding pocket of the kinase domain,
and the rapamycin binding residues in the FRB domain were then highlighted in the
models produced images of the models in Rasmol (Sayle & Milner-White 1995) can
be seen in Figs. 3.14-3.16.
Red Backbone = FRB domain
Yellow Backbone = Rapamycin Binding residues
Green Backbone = Linker
Blue Backbone = Kinase domain
Orange Backbone = Key residues in ATP binding pocket
Fig. 3.14, Cα trace of the model with domains and key residues highlighted.
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Red Spheres = FRB domain
Yellow Spheres = Rapamycin Binding residues
Green Spheres = Linker
Blue Spheres = Kinase domain
Orange Spheres = Key residues in ATP binding pocket
Fig. 3.15, Space-Filling view of the model centred on FRB’s rapamycin binding
residues.
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Red Spheres = FRB domain
Yellow Spheres = Rapamycin Binding residues
Green Spheres = Linker
Blue Spheres = Kinase domain
Orange Spheres = Key residues in ATP binding pocket
Fig. 3.16, Space-Filling view of the model centred on the key residues in the
Kinase domain’s ATP binding pocket.
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3.8) Discussion
A 3D model of mTOR from the FRB domain to the end of the kinase domain was
produced using comparative modelling. Key residues in the model were highlighted to
facilitate easy visualisation of the regions to which ATP or inhibitors would bind. A
major benefit that resulted from the project compared with Hall’s model was that a
model had been generated that would enable myself and other members of the group
to gain insight into potential mechanisms for the inhibition of mTOR.
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Chapter 4: Results
mTOR mutant studies
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Chapter 4: mTOR mutant studies
4.0) Introduction
An alternatively spliced form of mTOR was recently discovered in the Gout lab by
Alexander Zhyvoloup. This isoform was found in the cell lysate of HEK293 cells.
Analysis of the protein revealed that in contrast to the full-length wild-type mTOR, 12
amino acids were absent in this isoform’s kinase domain. This mutation removes the
entire kbeta5 strand from the catalytic site, which includes the critical Lys2187
residue. This amino acid is thought to interact with the α-phosphate of ATP.
Consequently, it is thought that the 12del mutation disrupts mTOR activity.
Furthermore, a Japanese lab recently created a point mutation (S2215Y) in mTORα’s
kinase domain (Sato et al. 2010). Figs. 4.1-4.3 illustrate the locations of these
mutations. Experiments showed that this alteration conferred constitutive activation
on mTORα, even under conditions of nutrient deprivation (Sato et al. 2010). We were
interested to see what potential effects these mutations could have on mTORβ activity.
Therefore, site-directed mutagenesis was utilised to introduce these mutations
into the DNA sequences of mTORβWT. This resulted in the creation of two different
types of mutant for mTORβ. The S2215Y point mutant was named ‘S2215Y’, and the
alternatively spliced form was denoted ‘12del’ in all future work. Sequence analysis
of the DNA was then performed in order to verify that the mutations were present.
HEK293 cells were then transiently transfected with the appropriate plasmid DNA
and Western blots were carried out to confirm expression of the proteins in the
mammalian cells. Immunoprecipitation was also performed in order to purify the
mTOR proteins from the HEK293 total cell lysates.
The effects of the mutations on mTORβ activity were then explored by
assessing the phosphorylation status of 4E-BP1, S6K1 and Akt with Western blots.
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4E-BP1 and S6K1 are known as substrates for mTORC1, whereas Akt has been
shown to be a phosphorylation target for mTORC2. In order to assess whether the
S2215Y point mutation also conferred constitutive activation on mTORβ, the
HEK293 cells were subjected to serum and nutrient starvation as has been performed
by Sato et al with mTORαS2215Y (Sato et al. 2010). Moreover, we also wished to
observe whether stimulation of HEK293 cells that had been starved would restore
phosphorylation of 4E-BP1, which would be indicative of mTORC1 activity.
Fig. 4.1, Locations of the mutations in mTORβ. mTORα shares the same C-
terminal region as mTORβ, so the position of the ‘12del’ mutation will be at the same
position in mTORα. The 12aa deletion is near the junction of the FRB and the Kinase
domains. It is thought to be an alternatively spliced form of mTOR. The S2215Y
point mutation was identified by searching the COSMIC database of somatic
mutations. It has been shown to confer constitutive activation on mTOR even under
conditions of nutrient deprivation.
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Red Spheres = FRB domain
Yellow Spheres = Rapamycin Binding residues
Green Spheres = Linker
Blue Spheres = Kinase domain
Orange Spheres = Key residues in ATP binding pocket
Purple Spheres = 12del mutation
Pink Spheres = S2215Y mutation
Fig. 4.2, Space-filled model of mTOR, from the N-terminus of the FRB domain
to the C-terminus of the Kinase domain, showing the locations of the 12del and
S2215Y mutations.
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Red Backbone = FRB domain
Yellow Backbone = Rapamycin Binding residues
Green Backbone = Linker
Blue Backbone = Kinase domain
Orange Backbone = Key residues in ATP binding pocket
Purple Backbone = 12del mutation
Pink Backbone = S2215Y mutation
Fig. 4.3, Backbone model of mTOR, from the N-terminus of the FRB domain to
the C-terminus of the Kinase domain showing the locations of the 12del and
S2215Y mutations.
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4.1) Agarose gel analysis of mutant mTORα and mTORβ mutant DNA
PCR site-directed mutagenesis was used to create the S2215Y and 12del mutations in
the mTORα and mTORβ containing plasmids. The mutant DNA was then amplified
and restriction analysis was performed on an agarose gel with Pvu2. This can be seen
in Fig. 4.4.
Fig. 4.4, Agarose gel of mTORβWT-myc/pcDNA3.1(+), mTORβS2215Y-
myc/pcDNA3.1(+) and mTOR12del-myc/pcDNA3.1(+) plasmids digested with
Pvu2. The plasmids were electrophoresed on a 0.75% agarose gel.
Digestion of the three plasmids with their respective inserts should result in an
identical pattern of bands for the WT and S2215Y point mutant. However, restriction
of the 12del mutant would produce the same set of fragments as the WT, with the
exception of a 505bp band in lieu of the WT’s 536bp band. Samples 1,3 and 4 of the
S2215Y mutants all possessed the same fragments as the mTORβWT, so they were
sent for sequence analysis. Similarly, the three 12del mutant samples that have been
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marked with red arrows all contain the critical 505bp band, indicative of a 12aa
deletion. These three samples were also dispatched for sequence analysis.
4.2) DNA sequence analysis of the mutant mTORβ DNA
Samples of the mTORβS2215Y, mTORβ12del and mTORα12del plasmids were sent
to GATC Biotech for DNA sequence analysis. Chromatograms showing the locations
of the S2215Y and 12del mutations are shown in Fig. 4.5 and Fig. 4.6. In Fig. 4.6, a
sequence alignment between mTORβWT and mTORβ12del in which the location of
the 12del deletion has been highlighted has also been included.
Fig. 4.5, Chromatogram showing mTORβS2215Y point mutation. Here one can
clearly see that the S2215Y point mutation (TCT to TAT) has been successfully
created in the mTORβWT-myc/pcDNA3.1(+) plasmid after mutagenesis.
Point mutation
Structural and Functional Analysis of mTORβ
106
A)
Clustalw alignment between mTORβWT and mTORβ12del mutant DNA after
sequence analysis
mTORBΔ12 GCCCCGGAAATTGACACTTATGGGC----------------------------------- 656
mTORBWT           GCCCCGGAAATTGACACTTATGGGCAGCAACGGACATGAGTTTGTTTTCCTTCTAAAAGG 1980
*************************
mTORBΔ12 -CATGAAGATCTGCGCCAGGATGAGCGTGTGATGCAGCTCTTCGGCCTGGTTAACACCCT 715
mTORBWT CCATGAAGATCTGCGCCAGGATGAGCGTGTGATGCAGCTCTTCGGCCTGGTTAACACCCT 2040
***********************************************************
B)
Fig. 4.6, Sequencing of the mTORβ12del mutation. (A) Sequence alignment
highlighting the deletion. (B) Chromatogram and sequence indicating the site of the
deletion.
36 NTs
deleted here
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4.3) Western Blot to confirm expression of the mTORβ proteins
HEK293 cells were defrosted and grown to a suitable confluency as described in the
Materials and Methods chapter. The cells were then transiently transfected with either
mTORβWTβ-myc/pcDNA3.1(+), mTORβS2215Y-myc/pcDNA3.1(+), mTORβ12del-
myc/pcDNA3.1(+) or empty pcDNA3.1(+) vector respectively. After 24hrs the cells
were lysed and the samples were loaded on a Bis-Tris gel. The proteins were then
detected by Western Blot analysis (Fig. 4.7) using anti-myc tag antibodies.
Fig. 4.7, Western Blot confirming expression of the mTORβWT and mutant
proteins in transiently transfected HEK293 cells. Φ denotes HEK293 cells
transiently transfected with empty pcDNA3.1(+) vector. The mTORβ proteins were
detected and non-specific binding was detected in the negative control lane Φ.
βWT βSS215Yβ12del Φ
80kDa
60kDa
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4.4) Immunoprecipitation of the mTORβ proteins
HEK293 cells that had been transiently transfected in the same manner as outlined in
section 2.3 above were also lysed, and the mTORβ proteins were purified by
immunoprecipitation using an anti-myc tag antibody. The protein samples purified by
immunoprecipitation were then detected by Western blotting using an anti-myc tag
primary antibody (Fig. 4.8).
Fig. 4.8, mTORβ proteins purified by immunoprecipitation from transiently
transfected HEK293 cell lysate and then detected by Western Blotting. Φ denotes
HEK293 cells transiently transfected with empty pcDNA3.1(+) vector.
80kDa
Φ βWT βS2215Y Β12del
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4.5) pAkt and Akt Western Blots
HEK293 cells were co-transfected with either empty pcDNA3.1(+) vector or with
pcDNA3.1(+) containing a mTORβ insert and Akt-WT-EE/pCMV3. The cells were
co-transfected with Akt-WT-EE/pCMV3 to increase the levels of Akt expressed in the
cell. This would augment the level of substrate that would be available for mTORβ
proteins to phosphorylate. Consequently, it would be easier to detect P-Akt and Akt
via Western Blotting and to observe whether mTORC2 activity was present.
Following serum and nutrient starvation, the cells were then lysed and Akt, PAkt and
the mTORβ proteins were detected by Western blotting. See Fig. 4.9. As expected, no
proteins were visible in the negative control lane and all mTOR proteins were
detected in Fig. 4.9A. Proteins were detected with Anti-myc antibody. Contrary to
expectation, PAkt was present in all the sample lanes in Fig. 4.9B. In the similar
experiment conducted with mTORα proteins by Sato et al (Sato, Nakashima, Guo,
Coffman, & Tamanoi 2010), the intensity of the PAkt bands for all samples were
negligible. Significant levels of Akt proteins were visible in all sample lanes in Fig.
4.9C, which demonstrated that high levels of Akt protein were expressed by the
HEK293 cells. In HEK293 cells which have been starved, little or no phosphorylation
of Akt should have occurred, since mTORC2 activity would be inhibited. A possible
explanation was that the cells were not starved for long enough to diminish mTORC2
activity.
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A)
B)
C)
Fig. 4.9, Western Blots showing detection of mTORβ (A), P-Akt (B) and Akt (C)
proteins respectively in HEK293 cells co-transfected with either empty
pcDNA3.1(+)  vector or with pcDNA3.1 containing a mTORβ insert and Akt-
WT-EE/pCMV3. In all figures Φ denotes HEK293 cells transiently transfected with
empty pcDNA3.1 (+) vector and was the negative control.
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4.6) pS6K1 and S6K1 Western Blots
HEK293 cells were co-transfected with either empty pcDNA3.1(+) vector or with
pcDNA3.1(+) containing a mTORβ insert and S6K1-EE/pcDNA3.1(+). Following
serum and nutrient starvation, the cells were then lysed and P-S6K1 and the mTORβ
proteins were detected by Western blotting. In order to ensure that equal quantities of
sample had been loaded onto each gel a Western Blot to detect the levels of actin was
also performed. The Western Blots to detect the various proteins can be seen in Fig.
4.10. In Fig. 4.10A, the mTOR proteins were all expressed, and no myc-tagged
proteins were detected in the negative control lane as was expected. Proteins were
detected with Anti-myc antibody. The level of actin visible was similar in each of the
sample lanes in Fig. 4.10B. This was evidence that equal quantities of sample had
been loaded into each well in the gel. Anti-Actin antibody was used to detect the
proteins. Surprisingly, P-S6K1 was discernible with every sample in Fig. 4.10C. This
was clear proof of the existence of mTORC1 activity in the starved HEK 293 cells.
Nutrient deprivation has been shown to diminish phosphorylation of S6K1 by
mTORC1, so this result was unanticipated. The PS6K1 present in the negative control
lane (Φ) could only be attributed to endogenous mTORC1. A potential explanation
was that the cells were not sufficiently starved to curtail protein synthesis, and as a
result mTORC1 activity was not diminished. Almost no S6K1-EE tagged protein was
detected in Fig. 4.10D with anti EE-tag antibody. A possible reason for these results
was that mTORC1 was active and phosphorylated almost all the cellular S6K1 to P-
S6K1, leaving little to be detected.
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D)
Fig. 4.10, Western Blots showing detection of the mTOR (A), actin (B), pS6K1 (C)
and S6K1 (D) proteins in HEK293 cells co-transfected with either empty
pcDNA3.1(+)  vector or with pcDNA3.1 containing a mTORβ insert and S6K1-
EE/pcDNA3.1(+). In all figures Φ denotes HEK293 cells transiently transfected with
empty pcDNA3.1(+) vector and was the negative control.
4.7) p4E-BP1 and 4E-BP1 Western Blots (Starvation only)
HEK293 cells were transiently transfected with empty pcDNA3.1(+) vector and
pcDNA3.1(+) vector containing a mTORβ insert. Following serum and nutrient
starvation, the cells were lysed and Western blots were performed. The mTORβ
proteins, p4E-BP1 and 4E-BP1 were probed for with the appropriate antibodies. The
blots are shown in Fig. 4.11. As one can see in Fig. 4.11A, the mTORβ proteins were
all well expressed, and no myc-tagged proteins was visible in the negative control
lane as expected. The mTORβ proteins were detected using Anti-myc antibodies. In
Fig. 4.11B, phosphorylated 4E-BP1 was present in significant quantities in every
sample lane, demonstrating the existence of mTORC1 activity. This was totally
contrary to expectations, since cells subjected to nutritional deprivation would not
have the resources to continue protein synthesis. A potential explanation could be that
the antibody that was used to detect P4E-BP1 was exceptionally efficient and was
capable of detecting truly minute quantities of phosphorylated protein. p4E-BP1 was
ΦβW
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β12del
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70kDa
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A-EE
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detected using anti phospho-4E-BP1 (Thr37/46) antibody. Large quantities of 4E-BP1
were detected in every sample lane in Fig. 4.11C using anti 4E-BP1 antibody. In cells
that had been starved one, would expect to see very low levels of mTORC1 activity,
hence the level of P4E-BP1 protein should be low and the amount of 4E-BP1 protein
should be high. Therefore, this result conformed to expectations.
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A)
B)
C)
Fig. 4.11, Western Blots showing expression of the mTORβ (A), p4E-BP1
(Thr37/46) (B) and 4E-BP1 (C) proteins in HEK293 cells transiently transfected
with pcDNA3.1(+) containing a mTORβ insert or empty pcDNA3.1(+) plasmid.
In all figures Φ denotes HEK293 cells transiently transfected with empty pcDNA3.1
vector and was the negative control.
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4.8) p4E-BP1 and 4E-BP1 Western Blots (Starvation followed by stimulation of
negative control)
The Western Blots outlined in section 2.7 were repeated with the exception that
HEK293 cells were serum starved for 24 hours rather than merely overnight.
Furthermore, nutrient starvation was carried out for 3 hours instead of 1 hour as had
been done with all previous experiments. HEK293 cells that had been transiently
transfected with an empty pcDNA3.1(+) plasmid were also stimulated for 1 hour with
complete media after being subjected to the same starvation conditions as the other
cells. This additional stimulated negative control was then loaded on the gels
alongside the standard negative control. There were two reasons for the variation in
experimental conditions. Firstly, we wanted to observe the effects of increasing the
duration of starvation upon mTORC1 activity, and secondly we wished to see whether
stimulation of cells would restore the levels of P4E-BP1. Western Blots to detect the
levels of mTORβ proteins, endogenous P4E-BP1 and 4E-BP1 were carried out and
the results can be seen in Fig. 4.12. As can be seen in Fig. 4.12A, expression of all the
mTORβ proteins was strong and no myc-tagged proteins were detected in any of the
negative control lanes as expected. The mTORβ proteins were detected using anti-
myc antibodies. In Fig. 4.12B above, starving the cells for a longer period resulted in
a drastic reduction in the levels of P4E-BP1 in all samples apart from the stimulated
negative control cells. These results suggested that prolonged starvation was
necessary in order to inhibit mTORC1 activity. Another conclusion was the S2215Y
point mutation did not confer constitutive activation on mTORβ. Stimulation of the
cells dramatically elevated the levels of P4E-BP1, as can be seen in the Φ (stimulated)
lane. In Fig. 4.12C, all of the cells that had been starved without subsequent
stimulation, 4E-BP1 was present. However, in the case of the Φ (stimulated) sample,
Structural and Functional Analysis of mTORβ
117
almost no 4E-BP1 was visible. This demonstrated that stimulation after starvation
rapidly restored mTORC1 activity, which phosphorylated large quantities of
endogenous 4E-BP1.
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C)
Fig. 4.12, Western Blots showing expression of the mTORβ proteins (A),
detection of endogenous p4E-BP1 (B) and 4E-BP1 in HEK293 cells transiently
transfected with pcDNA3.1(+) containing a mTORβ insert or empty
pCDNA3.1(+) vector. In all figures Φ (starved) denotes HEK293 cells transfected
with empty pcDNA3.1 vector that were starved and not stimulated. The Φ (stimulated)
sample consisted of HEK293 cells that had been transfected with empty pcDNA3.1(+)
vector, starved and then stimulated with complete media.
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4.9) Discussion
It was clear that the S2215Y and 12del mutations did not confer constitutive
activation on mTORβ. The most conclusive result that led to this conclusion is shown
in Fig 4.12. Under conditions of extended starvation, the HEK293 cells that had been
transiently transfected with the mTORβ mutant plasmids in Fig 4.12A did not display
high levels of P4E-BP1, which would be indicative of mTORC1 activity.  This led to
the suggestion that they were not oncogenic mutations, since hyperactive mTOR
signalling has been shown to be a hallmark of cancer. The 12del mutation results in
the deletion of the critical Lys2187 residue, which is thought to contact the α-
phosphate of ATP. Therefore, it was expected that the 12del mutation would inhibit
mTOR activity.
The results in Fig 4.12 also demonstrated that the extended starvation
conditions employed were required to bring about inhibition of mTORC1 activity. It
would be interesting to repeat the Western blots shown in Figs 4.9 and 4.10 to assess
the effect on Akt and S6K1 phosphorylation after prolonged starvation.
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Chapter 5: Results
Creating a mTORβ-
TapTag construct
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Chapter 5: Creating a mTORβ-TapTag construct
5.0) Introduction
The tandem affinity purification (TAP) method allows one to purify protein
complexes from endogenous sources. The system was developed by Rigaut et al.
(Rigaut et al. 1999) and was initially utilised in yeast cells. Subsequently, it was
discovered that the technique could also be used with mammalian tissues. The
principle behind the TAP methodology involves the fusion of the TAP tag to the N or
C terminus of the protein of interest. The construct is then introduced into the
organism or host cell. Cellular extracts are then prepared and the fusion protein and
any potential binding partners are purified in two specific purification/elution stages.
If one desires to characterise protein complexes, then the proteins recovered must be
concentrated and fractionated on a denaturing gel prior to elucidation by mass
spectrometry. Furthermore, since the TAP technique is relatively gentle, damage to
the proteins during purification is highly unlikely. Consequently, the purified proteins
can be tested for their activities in various assays or utilised in structural studies (Puig
et al. 2001). The high yield and simplicity of the TAP method makes it a very
attractive tool to use for protein purification and elucidation of their functions. A
diagram showing the classical TAP tag is shown in Fig. 5.1.
Over the years, numerous modifications and improvements to the first TAP
tag have been made. These adaptations have principally been introduced in order to
improve the recovery of protein complexes in mammalian systems. The TAP tag that
I used was a GS-TAP tag (Fig. 5.2). This was fused to the N-terminus of the mTORβ
protein. The advantages offered by the GS-TAP tag over the ProtA and CBP TAP tag
combination include higher yield of bait protein (mTORβ) and fewer contaminants.
An overview of the tandem affinity purification process using the GS-TAP tag is
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shown in Fig. 5.3. Unfortunately, there was insufficient time to carry out purifications
of the fusion protein from HEK293 cells, but the recombinant protein was created.
This will allow future students to continue the work that I have started.
Fig. 5.1, Schematic showing the original TAP tag. The classical TAP tag consists of
CBP and ProtA with a TEV protease cleavage site in the intervening region. As
shown below, the TAP-tag construct can be fused either N or C terminally to the
protein of interest. (Taken from (Li 2011))
Fig. 5.2, Schematic of the GS-TAP tag fused to the N-terminus of mTOR. The
protein A modules have been replaced with 2 protein G modules and the calmodulin
binding peptide has been replaced by a streptavidin binding peptide. A TEV protease
cleavage site is situated in between the protein G modules and the streptavidin
binding peptide. The GS-TAP tag offers superior recovery of bait protein with fewer
associated contaminants compared to the protein A/CBP TAP tag depicted in Fig. 5.1.
Protein G Protein G TEV SBP mTORβ
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Fig. 5.3, Overview of the tandem affinity purification procedure using a GS-TAP
tag. The tandem-affinity-purification (TAP) tag is composed of three components: a
streptavidin-binding peptide, a tobacco etch virus (TEV) protease cleavage site and
Protein G as immunoglobulin G (IgG)-binding domains. Cells or organisms are
produced that contain TAP-tagged protein(s). Cells expressing the fusion protein are
lysed and TAP is performed. The first column contains IgG beads. TEV protease
cleavage releases SBP-mTORβWT. An additional round of binding is performed on a
second column that consists of Streptavidin-binding peptide beads. The native
complex is then eluted.
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Results
5.1) Using PCR to introduce XhoI and NotI restrictions sites into
mTORβWT/pcDNA3.1(+)
mTORβWT was not cloned into the pcDNA3.1(+) vector using the XhoI and NotI
restriction enzymes. Therefore, it was not possible to excise it from its original vector
and directly clone it into the TAP-tag plasmid pCeMM-NTAP(GS), which contained
XhoI and NotI restriction sequences. As a result, primers were designed that would
allow the XhoI and NotI restriction sequences to be artificially introduced at the N
and C termini of mTORβ respectively by PCR. See the materials and methods chapter
for details of the PCR reaction conditions utilised. After PCR amplification had been
performed, the PCR reaction mixtures were analysed on an agarose gel. This can be
seen in Fig. 5.4. The PCR product was successfully produced in all cases. Addition of
DMSO appeared to increase the production of high MW impurities, but also
diminished the presence of lower MW contaminants. DMSO also had the effect of
decreasing the yield of PCR product. The samples in lanes 2 and 3 were purified using
ethanol precipitation and the other PCR reaction mixtures were frozen.
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Fig. 5.4, The PCR reaction mixtures were analysed on a 0.75% agarose gel. A
range of reaction conditions were used in order to ascertain those that would produce
the most PCR product. MW was the Fermentas Generuler DNA ladder used to
ascertain the size of the fragments. The samples in lane 1-4 were PCR reaction
mixtures, where PCR was performed at 62°C. Samples 5-6 were PCR reaction
mixtures containing DMSO, where reactions were carried out at 60°C. Samples 7-8
were PCR reaction mixtures with DMSO, and PCR was conducted at 62°C. Samples
9-10 were PCR reaction mixtures containing DMSO, and PCR was performed at 64°C.
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5.2) Agarose gel analysis of XhoI and NotI restriction of pCeMM-NTAP(GS) and
mTORB PCR product
The PCR products that had been purified by ethanol precipitation and the TAP tag
plasmid (pCeMM-NTAP(GS)) were restricted with XhoI and NotI enzymes. This
resulted in the linearisation of the plasmid and digestion of the ends of the linear PCR
product. In order to confirm that the digested DNA was of the correct size and of
good quality, the DNA was analysed on an agarose gel. The result is shown in Fig.
5.5. The vectors were linearised successfully as can be seen in the agarose gel and the
DNA fragments were all of the expected size. The agarose gel was placed on a UV
light box and the relevant bands were excised from the gel. Promega’s Wizard SV gel
and PCR clean-up system was utilised to purify the gel fragments. From the gel, it
was estimated that the concentration of the PCR product in lane 2 was 20ng/μL and in
lane 3 was 8ng/μL.
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Fig. 5.5, pCeMM-NTAP(GS) and PCR product (mTORβ/pcDNA3.1(+) with
XhoI and NotI restriction sequences) were linearised by restriction with XhoI
and NotI. The digested DNA was run on a 0.75% agarose gel. MW was the
Fermentas Generuler DNA ladder used to ascertain the size of the fragments. Lane 1
contained a DNA Quantity Marker (0.1μg/μL), which was used to deduce the DNA
concentration of the other samples. Lanes 2 and 3 were linearsied mTORβPCR
products Clones 1 and 2 respectively. The sample in lane 4 was the linearised
pCeMM-NTAP(GS) vector.
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5.3) Ligation of mTORβ to pCeMM-NTAP(GS), amplification and agarose gel
analysis
After the DNA fragments had been purified from the agarose gel, the mTORβ PCR
product was ligated to the pCeMM-NTAP(GS) vector. The ligated DNA was then
transformed into E.coli XL-10 competent cells. After growth on selective agar plates,
colonies were seeded into LB with selective antibiotics and then purified with a mini-
prep kit. The DNA obtained was restricted with XhoI and NotI and analysed on an
agarose gel, shown in Fig. 5.6.
Fig. 5.6, 0.75% Agarose gel analysis of XhoI/NotI digestion of mTORB/pCeMM-
NTAP(GS) Clone 1 and pCeMM-NTAP(GS). MW was the Fermentas Generuler
DNA ladder used to ascertain the size of the fragments. Lane 1 contained linearised
mTORβ/pCeMM-NTAP(GS) Clone 1. Lane 2 contained linearised pCeMM-
NTAP(GS). Digestion of the recombinant DNA product produced by DNA ligation
resulted in the generation of the linearised mTORβWT insert and pCeMM-NTAP(GS)
vector. This was proof that the cloning had been successfully performed.
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5.4) Expression of mTORβ/pCeMM-NTAP(GS) in HEK293 cells
HEK293 cells were then transiently transfected with mTORβ/pCeMM-NTAP(GS)
Clones 1 and 2, pCeMM-NTAP(GS) and mTORβ/pcDNA3.1(+) when they had
reached a suitable confluency. After 72 hours the cells were lysed and the total cell
lysates were mixed with SDS and run on a protein polyacrylamide gel. mTORα,
mTORβ and mTORβ/pCeMM-NTAP(GS) were then detected on a Western blot using
an anti Phospho-mTOR S2448 antibody. This can be seen in Fig. 5.7. mTORα and
mTORβ were detected in all sample lanes as expected since both proteins are
endogenous and possess a S2448 phosphorylation site. The mTORβ/NTAP(GS)
protein was also present in lanes 3 and 4, which were cell lysates from HEK293 cells
transiently transfected with Clones 1 and 2 respectively. This proved that transfection
had been successful and that the HEK293 cells were capable of expressing the fusion
protein.
Fig. 5.7, Western blot of total cell lysate of HEK293 cells transiently transfected
with mTORβ/pcDNA3.1(+), pCeMM-NTAP(GS) and mTORβ/pCeMM-
NTAP(GS) clones 1 and 2. The primary AB used was anti Phospho-mTOR S2448.
Akt phosphorylates mTORα and mTORβ at S2448. The sample in lane 1 was
mTORβ/pcDNA3.1(+) and lane 2 contained pCeMM-NTAP(GS). Lanes 3 and 4 were
mTORβ/pCeMM-NTAP(GS) Clones 1 and 2 respectively.
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5.5) Affinity purification of mTORβ/NTAP(GS) with Protein G Sepharose beads
and Western Blotting
Affinity purification with Protein G sepharose beads was performed with the soluble
fractions of HEK293 total cell lysates. The HEK293 cells were transiently transfected
in the same manner outlined in section 5.4. Proteins were detected with Western
Blotting. For the first blot, an anti phospho-mTOR S2448 mTOR primary antibody
was used, and for the second blot an anti mTOR C-terminal primary antibody was
utilised. The blots are shown in Fig. 5.8. In Fig. 5.8(A), large quantities of
mTORβ/NTAP(GS) were purified using protein G sepharose beads in lanes 3 and 4,
demonstrating that the affinity purification was successful and that the fusion protein
was expressed. No protein of similar MW was detected in lanes 1 and 2, proving that
the 100kDa protein in lanes 3 and 4 was not merely the result of non specific binding.
Far more fusion protein was visible compared to mTORβ, which again showed that
affinity purification was effective. In Fig. 5.8(B) even larger quantities of
mTORβ/NTAP(GS) were detected using anti mTOR C-terminal primary antibody.
This blot also demonstrated that affinity purification with Protein G sepharose beads
was successful and that the fusion protein was expressed in transiently transfected
HEK293 cells.
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A)
B)
Fig. 5.8, Affinity purification of mTORβ/NTAP(GS) Protein G Sepharose beads
and subsequent Western blots using Anti-Phospho-mTOR S2448 (A) and anti-
mTOR C-terminal (B) primary ABs to detect mTORβ/NTAP(GS) fusion protein
in transiently transfected HEK293 cells. (A) Lanes 1 and 2 contained
mTORβ/pCeMM-NTAP(GS) clones 1 and 2. Lanes 3 and 4 contained pCeMM-
NTAP(GS) and mTORβ-myc/pcDNA3.1(+) respectively. (B) Lane 1 contained
mTORβ/pCeMM-NTAP(GS) Clone 1. Lanes 2 and 3 were pCeMM-NTAP(GS) and
mTORβ-myc/pcDNA3.1(+) respectively.
4321
25kDa
70kDa
100kDa
130kDa
170kDa
mTORβ (80kDa)
mTORβ/NTAP(GS)
fusion protein
(100kDa)
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5.6 Discussion
The full coding sequence of mTORβ was successfully cloned into the pCeMM-
NTAP(GS) vector, with the N-terminal TAP-tag positioned at the N-terminus of
mTORβ. Expression of the fusion protein in transiently transfected HEK293 cells was
also confirmed. Affinity purification with Protein G sepharose beads appeared to be
efficient, owing to the copious amounts of proteins that could be detected by Western
blotting. Future work would involve testing whether known mTORβ binding partners
such as Rictor and Raptor, (Panasyuk et al. 2009) can be efficiently co-purified using
the mTORβ/NTAP(GS) fusion protein that has been created. It is my hope that new
binding partners are subsequently discovered and their functions in the mTOR
signalling pathway elucidated.
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Chapter 6
General Discussion
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Chapter 6: General Discussion
Advances in the understanding of mTOR function have been hampered by the lack of
a mTOR crystal structure. The principal problem encountered has been the difficulty
in obtaining sufficient quantities of soluble protein for crystallisation studies. In order
to overcome this challenge it was decided to make a departure from conventional
practice. Instead of expressing mTOR protein in mammalian cells which has been the
accepted methodology, insect cells were transfected. In addition, insect cells were co-
transfected with plasmids containing Rictor and Raptor. It was hoped that co-
expression of either Rictor or Raptor with mTOR would increase its solubility, and
hence the quantity of protein that would be available for crystallographic analysis.
With regard to the first objective, we were not disappointed. Rictor, Raptor and
mTOR were all successfully purified from cellular lysates using immunoprecipitation
and Western Blotting confirmed their expression. However, solubilising adequate
mTOR protein still proved to be elusive. Although the results from this work have not
been presented in this thesis, they did influence the direction of my subsequent studies.
Consequently, it was decided to model the Kinase domain of mTORβ using in silico
methods. This approach would be rapid, cheap and offer a reasonably accurate model
of mTORβ’s active region.
A 3D model of mTOR’s kinase domain, with the FRB domain positioned in
an adjacent location was created using the technique of comparative modelling. This
model allowed us to visualise the ATP binding pocket of mTOR. Furthermore, the
model also allowed me to visualise the location of the S2215Y and 12del mutations in
mTOR with respect to the catalytic pocket. Hence the model could be used as a tool to
understand experimental results. However, the additional experiments that have been
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proposed in the discussion for chapter 4 would most certainly be necessary before
sufficient data had been generated to propose potential regulatory mechanisms. Time
did not permit me to model the full length mTOR protein or any of the proteins that
are components of the mTOR complexes. Provided that suitable homologue proteins
exist for each domain, it would be useful to model both mTORα and mTORβ in their
entirety. This would potentially give us greater insight into the protein’s function and
inhibition. Molecular docking studies with FKBP12-rapamycin, rapalogues and ATP-
competitive inhibitors also offer scope for future work. A full-length mTOR model
might also be useful for understanding the interaction of novel mTORβ binding
partners with mTORβ, if any should be discovered in the future using the mTORβ-
NTAP(GS) fusion protein that I have created.
The S2215Y and 12del mutations were also introduced into mTORβ. The
point mutation S2215Y has been shown to convey constitutive activation on mTORα.
In contrast the 12del mutation removes the entire kbeta5 strand from the catalytic site,
which includes the critical Lys2187 residue. This amino acid is thought to interact
with the α-phosphate of ATP. Consequently, it is thought that the 12del mutation
disrupts mTOR activity. The effects that these mutations had on the phosphorylation
of the mTOR substrates Akt, S6K1 and 4E-BP1 following starvation was assessed. It
was shown that under the initial starvation conditions employed (overnight serum
starvation and 1hr nutrient starvation), mTOR activity was unimpaired. However,
when the HEK293 cells were starved for an extended period (24hr serum starvation
and 3hr nutrient starvation) and then stimulated (incubation in complete medium for
1hr), the results conformed to expectations. Augmenting the duration of starvation
had the desired effect of inhibiting mTOR activity. This also lent further weight to my
previous supposition that the original starvation conditions employed were
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insufficient to inhibit mTOR activity. Stimulation fully restored mTORC1 activity, as
shown by the detection of P-4E-BP1 in cells transiently transfected with just empty
vector. It would also be interesting to assess the effect that stimulation would have on
cells that were transfected with mTORβWT and the mTORβ mutant plasmids. Also of
interest, would be to repeat the experiments with the addition of a sample of cells that
had been transfected with a plasmid containing mTORαS2215Y. Isolation of the
mutant and WT proteins by immunoprecipitation followed by in vitro kinase assays
would also be informative. The benefit of conducting these experiments would be that
any mTOR activity present could only be attributed to the purified protein. A
disadvantage would be that intracellular mTOR complex components that are
requisite for mTOR activity may be lost in the immunoprecipitation.
A mTORβ-NTAP(GS) fusion protein was also successfully created.
Unfortunately, there was not enough time for me to perform a preliminary tandem
affinity purification. Nevertheless, the student that continues my work will be able to
use the bait protein that I have generated to search for novel mTORβ binding partners.
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